Skip Navigation
Skip to contents

Intest Res : Intestinal Research

IMPACT FACTOR

Most download

Page Path
HOME > Browse articles > Most download
123 Most download
Filter
Filter
Article category
Keywords
Publication year
Authors
Funded articles

The most downloaded articles in the last three months among those published since 2023.

Review
IBD
Optimizing 5-aminosalicylate for moderate ulcerative colitis: expert recommendations from the Asia-Pacific, Middle East, and Africa Inflammatory Bowel Disease Coalition
Filiz Akyüz, Yoon Kyo An, Jakob Begun, Satimai Aniwan, Huu Hoang Bui, Webber Chan, Chang Hwan Choi, Nazeer Chopdat, Susan J Connor, Devendra Desai, Emma Flanagan, Taku Kobayashi, Allen Yu-Hung Lai, Rupert W Leong, Alex Hwong-Ruey Leow, Wai Keung Leung, Julajak Limsrivilai, Virly Nanda Muzellina, Kiran Peddi, Zhihua Ran, Shu Chen Wei, Jose Sollano, Michelle Mui Hian Teo, Kaichun Wu, Byong Duk Ye, Choon Jin Ooi
Intest Res 2025;23(1):37-55.   Published online November 4, 2024
DOI: https://doi.org/10.5217/ir.2024.00089
AbstractAbstract PDFPubReaderePub
The lack of clear definition and classification for “moderate ulcerative colitis (UC)” creates ambiguity regarding the suitability of step-up versus top-down treatment approaches. In this paper, experts address crucial gaps in assessing and managing moderate UC. The Asia-Pacific, Middle East, and Africa Inflammatory Bowel Disease Coalition comprised 24 experts who convened to share, discuss and vote electronically on management recommendations for moderate UC. Experts emphasized that the goal of treating UC is to attain clinical, biomarker, and endoscopic remission using cost-effective strategies such as 5-aminosalicylates (5-ASAs), well-tolerated therapy that can be optimized to improve outcomes. Experts agreed that 5-ASA therapy could be optimized by maximizing dosage (4 g/day for induction of remission), combining oral and topical administration, extending treatment duration beyond 8 weeks, and enhancing patient adherence through personalized counselling and reduced pill burden. Treatment escalation should ideally be reserved for patients with predictors of aggressive disease or those who do not respond to 5-ASA optimization. Premature treatment escalation to advanced therapies (including biologics and oral small molecules) may have long-term health and financial consequences. This paper provides consensus-based expert recommendations and a treatment algorithm, based on current evidence and practices, to assist decision-making in real-world settings.

Citations

Citations to this article as recorded by  
  • Inflammatory bowel disease in Africa: the current landscape of pharmacological treatments and the promise of emerging innovations
    Murtada A. Oshi
    Exploration of Drug Science.2025;[Epub]     CrossRef
  • 6,437 View
  • 287 Download
  • 1 Web of Science
  • 1 Crossref
Close layer
Statements
IBD
Role of 5-aminosalicylic acid in ulcerative colitis management in 8 Asian territories: a physician survey
Julajak Limsrivilai, Allen Yu-hung Lai, Silvia T. H. Li, Murdani Abdullah, Raja Affendi Raja Ali, Satimai Aniwan, Hoang Huu Bui, Jen-Wei Chou, Ida Normiha Hilmi, Wee Chian Lim, Jose Sollano, Michelle Mui Hian Teo, Shu-Chen Wei, Wai Keung Leung
Intest Res 2025;23(2):117-128.   Published online January 6, 2025
DOI: https://doi.org/10.5217/ir.2024.00085
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Clinical guidelines typically endorse conventional therapies such as 5-aminosalicylic acid (5-ASA) as the mainstay of ulcerative colitis management. However, the degree of adoption and application of guideline recommendations by physicians within Asia remains unclear. This study aims to understand the prescribing patterns of 5-ASA and implementation of current guideline recommendations across Asian clinical practice. A physician survey was conducted among inflammatory bowel disease specialists in 8 Asian territories to understand practices and preferences in ulcerative colitis management, focusing on the use of 5-ASA and concordance with guideline recommendations. Survey findings were validated by country experts in diverse healthcare settings. Subgroup analyses stratified data by income levels and treatment reimbursement status. Ninety-eight valid responses were received from inflammatory bowel disease specialists or gastroenterologists among 8 economic entities. Significant differences were found in clinical practices and treatment preferences for ulcerative colitis management among different income-level and government-subsidy groups. Survey results are summarized in 8 findings that illustrate trends in 5-ASA use and guideline implementation across Asian territories. This study emphasizes socioeconomic factors that impact the adoption of guideline recommendations in real-world practice. Our findings indicate an eclectic approach to guideline implementation across Asia, based on resource availability and feasibility of treatment goals.
  • 4,080 View
  • 189 Download
Close layer
IBD
Management of ulcerative colitis in Taiwan: consensus guideline of the Taiwan Society of Inflammatory Bowel Disease updated in 2023
Hsu-Heng Yen, Jia-Feng Wu, Horng-Yuan Wang, Ting-An Chang, Chung-Hsin Chang, Chen-Wang Chang, Te-Hsin Chao, Jen-Wei Chou, Yenn-Hwei Chou, Chiao-Hsiung Chuang, Wen-Hung Hsu, Tzu-Chi Hsu, Tien-Yu Huang, Tsung-I Hung, Puo-Hsien Le, Chun-Che Lin, Chun-Chi Lin, Ching-Pin Lin, Jen-Kou Lin, Wei-Chen Lin, Yen-Hsuan Ni, Ming-Jium Shieh, I-Lun Shih, Chia-Tung Shun, Tzung-Jiun Tsai, Cheng-Yi Wang, Meng-Tzu Weng, Jau-Min Wong, Deng-Chyang Wu, Shu-Chen Wei
Intest Res 2024;22(3):213-249.   Published online July 29, 2024
DOI: https://doi.org/10.5217/ir.2023.00050
AbstractAbstract PDFPubReaderePub
Ulcerative colitis (UC) is a chronic inflammation of the gastrointestinal tract and is characterized by alternating periods of inflammation and remission. Although UC incidence is lower in Taiwan than in Western countries, its impact remains considerable, demanding updated guidelines for addressing local healthcare challenges and patient needs. The revised guidelines employ international standards and recent research, emphasizing practical implementation within the Taiwanese healthcare system. Since the inception of the guidelines in 2017, the Taiwan Society of Inflammatory Bowel Disease has acknowledged the need for ongoing revisions to incorporate emerging therapeutic options and evolving disease management practices. This updated guideline aims to align UC management with local contexts, ensuring comprehensive and context-specific recommendations, thereby raising the standard of care for UC patients in Taiwan. By adapting and optimizing international protocols for local relevance, these efforts seek to enhance health outcomes for patients with UC.

Citations

Citations to this article as recorded by  
  • Short-term and long-term outcomes of acute severe ulcerative colitis in Taiwan: a multicenter study with pre- and post-biologics comparison
    Wei-Chen Lin, Chun-Chi Lin, Wen-Hung Hsu, Feng-Fan Chiang, Chen-Wang Chang, Tzu-Chi Hsu, Deng-Chyang Wu, Horng-Yuan Wang, Jau-Min Wong, Shu-Chen Wei
    Intestinal Research.2025;[Epub]     CrossRef
  • Endoscopic Techniques for Colorectal Neoplasia Surveillance in Inflammatory Bowel Disease: A Systematic Review and Network Meta‐Analysis
    Chih‐Wen Huang, Hsu‐Heng Yen, Yang‐Yuan Chen
    United European Gastroenterology Journal.2025;[Epub]     CrossRef
  • Herpes zoster infection in patients with inflammatory bowel disease
    Dong Hyun Kim, Sang-Bum Kang
    The Korean Journal of Internal Medicine.2025; 40(3): 347.     CrossRef
  • Annual Therapeutic Drug Monitoring in Patients with Inflammatory Bowel Disease During Infliximab Maintenance Therapy: Balancing Efficacy with Risk of Pharmacokinetic Failure
    Yujin Lim, Boram Park, Kyeongman Jeon, Ok Soon Jeong, Eun Ran Kim, Young-Ho Kim, Dong Kyung Chang, Sung Noh Hong
    Digestive Diseases and Sciences.2025;[Epub]     CrossRef
  • Impact of Obesity on the Long-Term Outcomes of Advanced Therapies in IBD: A Real-World Study in Taiwan
    Wei-Chun Hsu, Shih-Hua Lin, Chia-Jung Kuo, Horng-Yih Chiu, Chien-Ming Chen, Ming-Yao Su, Cheng-Tang Chiu, Chen-Wang Chang, Tien-Yu Huang, Yu-Bin Pan, Puo-Hsien Le
    Journal of Inflammation Research.2025; Volume 18: 7139.     CrossRef
  • Serological Assessment of Hepatitis in Patients with Inflammatory Bowel Disease in Taiwan: A Retrospective Cohort Analysis
    Yueh-An Lee, Hsu-Heng Yen, Yang-Yuan Chen
    Life.2025; 15(6): 893.     CrossRef
  • Guselkumab in East Asians With Moderate‐to‐Severe Ulcerative Colitis: Subgroup Analysis of the QUASAR Induction and Maintenance Studies
    Baili Chen, Byong Duk Ye, Qian Cao, Fumihito Hirai, Masayuki Saruta, Minhu Chen, Susan Pelak, Nicole Shipitofsky, Ye Miao, Keira Herr, Bryan Wahking, Jianmin Zhuo, Tadakazu Hisamatsu
    Journal of Gastroenterology and Hepatology.2025;[Epub]     CrossRef
  • Rescue Therapies for Steroid-refractory Acute Severe Ulcerative Colitis: A Systematic Review and Network Meta-analysis
    Chih-Wen Huang, Hsu-Heng Yen, Yang-Yuan Chen
    Journal of Crohn's and Colitis.2024; 18(12): 2063.     CrossRef
  • High prevalence of vitamin D deficiency in Taiwanese patients with inflammatory bowel disease
    Chen-Ta Yang, Hsu-Heng Yen, Pei-Yuan Su, Yang-Yuan Chen, Siou-Ping Huang
    Scientific Reports.2024;[Epub]     CrossRef
  • 8,140 View
  • 310 Download
  • 7 Web of Science
  • 9 Crossref
Close layer
Review
IBD
Animal models of inflammatory bowel disease: novel experiments for revealing pathogenesis of colitis, fibrosis, and colitis-associated colon cancer
Chan Hyung Lee, Seong-Joon Koh, Zaher A Radi, Aida Habtezion
Intest Res 2023;21(3):295-305.   Published online May 31, 2023
DOI: https://doi.org/10.5217/ir.2023.00029
AbstractAbstract PDFPubReaderePub
Inflammatory bowel disease (IBD), comprising Crohn’s disease and ulcerative colitis, is a lifelong disease that manifests with chronic intestinal inflammation, sequential fibrosis, and an increased risk of colitis-associated colon cancer (CAC). The combined effects of genetic, immunological, environmental, and microbial factors render it difficult to determine the specific mechanism underlying the induction and perpetuation of IBD. Various animal models of IBD have contributed enormously to the understanding of IBD pathogenesis in terms of genomics, transcriptomics, proteomics, microbiome, and drug development of novel therapeutics. Although comprehensive research on IBD has been enabled by advanced technologies, such as genetically engineered models, there is a great need to develop relevant in vivo models of colitis and fibrosis. Here, we review 4 categories of animal models of acute and chronic intestinal inflammation, fibrosis, and CAC: chemically induced, genetically engineered, T cell transfer, and spontaneous gene mutation models.

Citations

Citations to this article as recorded by  
  • Estrogen Receptor β Activation Mitigates Colitis-associated Intestinal Fibrosis via Inhibition of TGF-β/Smad and TLR4/MyD88/NF-κB Signaling Pathways
    Fangmei Ling, Yidong Chen, Junrong Li, Mingyang Xu, Gengqing Song, Lei Tu, Huan Wang, Shuang Li, Liangru Zhu
    Inflammatory Bowel Diseases.2025; 31(1): 11.     CrossRef
  • Leveraging Organ‐on‐Chip Models to Investigate Host–Microbiota Dynamics and Targeted Therapies for Inflammatory Bowel Disease
    Tim Kaden, Raquel Alonso‐Román, Johannes Stallhofer, Mark S. Gresnigt, Bernhard Hube, Alexander S. Mosig
    Advanced Healthcare Materials.2025;[Epub]     CrossRef
  • Fructosyl-mangiferin ameliorates dextran sulfate sodium-induced colitis in mice via the STAT3/M1/Th17 axis
    Penghong Xu, Yuping Qian, Guo Xu, Jianlin Chu, Bingfang He
    Phytomedicine.2025; 139: 156475.     CrossRef
  • S1PR1-biased activation drives the resolution of endothelial dysfunction-associated inflammatory diseases by maintaining endothelial integrity
    Huaping Zheng, Jingjing Yu, Luhua Gao, Kexin Wang, Zheng Xu, Zhen Zeng, Kun Zheng, Xiaoju Tang, Xiaowen Tian, Qing Zhao, Jie Zhao, Huajing Wan, Zhongwei Cao, Kang Zhang, Jingqiu Cheng, Jürgen Brosius, Hu Zhang, Wei Li, Wei Yan, Zhenhua Shao, Fengming Luo,
    Nature Communications.2025;[Epub]     CrossRef
  • Groundwater Nitrate Contamination and its Effect on Human Health: A Review
    Indra Jeet Chaudhary, Ratna Chauhan, Sanjay Sarjerao Kale, Suresh Gosavi, Dheeraj Rathore, Vinay Dwivedi, Sunita Singh, Virendra Kumar Yadav
    Water Conservation Science and Engineering.2025;[Epub]     CrossRef
  • Standardization of a Preclinical Colon Cancer Model in Male and Female BALB/c Mice: Macroscopic and Microscopic Characterization from Pre-Neoplastic to Tumoral Lesions
    Elizabeth Correa, Juan Pablo Rendón, Vanesa Bedoya-Betancur, Juliana Montoya, Julian Muñoz Duque, Tonny W. Naranjo
    Biomedicines.2025; 13(4): 939.     CrossRef
  • Metabolic Disorders and Inflammatory Bowel Diseases
    Hye Kyung Hyun, Jae Hee Cheon
    Gut and Liver.2025; 19(3): 307.     CrossRef
  • Approaches, Strategies and Procedures for Identifying Anti-Inflammatory Drug Lead Molecules from Natural Products
    Tenzin Jamtsho, Karma Yeshi, Matthew J. Perry, Alex Loukas, Phurpa Wangchuk
    Pharmaceuticals.2024; 17(3): 283.     CrossRef
  • Strategies for targeting cytokines in inflammatory bowel disease
    Markus F. Neurath
    Nature Reviews Immunology.2024; 24(8): 559.     CrossRef
  • Inhibiting the cGAS-STING Pathway in Ulcerative Colitis with Programmable Micelles
    Saji Uthaman, Shadi Parvinroo, Ansuja Pulickal Mathew, Xinglin Jia, Belen Hernandez, Alexandra Proctor, Karuna Anna Sajeevan, Ariel Nenninger, Mary-Jane Long, In-Kyu Park, Ratul Chowdhury, Gregory J. Phillips, Michael J. Wannemuehler, Rizia Bardhan
    ACS Nano.2024; 18(19): 12117.     CrossRef
  • Targeting cyclooxygenase-2 for chemoprevention of inflammation-associated intestinal carcinogenesis: An update
    Kyung-Soo Chun, Eun-Hee Kim, Do-Hee Kim, Na-Young Song, Wonki Kim, Hye-Kyung Na, Young-Joon Surh
    Biochemical Pharmacology.2024; 228: 116259.     CrossRef
  • Lactobacillus paracasei Jlus66 relieves DSS-induced ulcerative colitis in a murine model by maintaining intestinal barrier integrity, inhibiting inflammation, and improving intestinal microbiota structure
    Fazheng Yu, Xiaoxu Wang, Honglin Ren, Jiang Chang, Jian Guo, Zhaoqi He, Ruoran Shi, Xueyu Hu, Yuanyuan Jin, Shiying Lu, Yansong Li, Zengshan Liu, Pan Hu
    European Journal of Nutrition.2024; 63(6): 2185.     CrossRef
  • Predictors of histologic remission in patients with biologic-naïve, moderate-to-severe ulcerative colitis treated with first-line biologic agents and small-molecule drugs: a single-center, retrospective cohort study
    Kijae Jo, Kwang Woo Kim, Hyun Jung Lee, Jong Pil Im, Joo Sung Kim, Seong-Joon Koh
    Intestinal Research.2024; 22(4): 453.     CrossRef
  • Interventional Effects of Lactobacillus plantarum Hfy04 Isolated from Naturally Fermented Yak Yogurt on Oxazolone-Induced Colitis in BALB/c Mice
    Haitao Zheng, Xiaoli Ping, Ruizi Wu, Cen Lei, Huijia Mao, Yanni Pan, Yongpeng He, Xin Zhao
    International Journal of Pharmacology.2024; 20(5): 817.     CrossRef
  • Inhibition of myeloperoxidase by food-derived peptides: A review of current research and future prospects
    Fai-Chu Wong, Yit-Lai Chow, Sheri-Ann Tan, Lingmin Tian, Weibin Bai, Tsun-Thai Chai
    Food Bioscience.2024; 60: 104458.     CrossRef
  • Deciphering Microbial Composition in Patients with Inflammatory Bowel Disease: Implications for Therapeutic Response to Biologic Agents
    Orazio Palmieri, Fabrizio Bossa, Stefano Castellana, Tiziana Latiano, Sonia Carparelli, Giuseppina Martino, Manuel Mangoni, Giuseppe Corritore, Marianna Nardella, Maria Guerra, Giuseppe Biscaglia, Francesco Perri, Tommaso Mazza, Anna Latiano
    Microorganisms.2024; 12(7): 1260.     CrossRef
  • Protective effect of freeze-dried extract of Persicaria bistorta Samp. on acetic acid-induced colitis model in rats: Involvement of nitric oxide and opioid system
    Niusha Esmaealzadeh, Amirhossein Abdolghaffari, Maryam Baeeri, Maede Hasanpour, Mehrdad Iranshahi, Cristina Santarcangelo, Mahdi Gholami, Roodabeh Bahramsoltani
    Inflammopharmacology.2024; 32(6): 3845.     CrossRef
  • Advances in Vascular Diagnostics using Magnetic Particle Imaging (MPI) for Blood Circulation Assessment
    Marisa O Pacheco, Isabelle K Gerzenshtein, Whitney L Stoppel, Carlos M Rinaldi‐Ramos
    Advanced Healthcare Materials.2024;[Epub]     CrossRef
  • Immunomodulatory Effects of a Probiotic Mixture: Alleviating Colitis in a Mouse Model through Modulation of Cell Activation Markers and the Gut Microbiota
    Hye-Myung Ryu, S. M. Shamsul Islam, Bushra Riaz, Hasan M. Sayeed, Bunsoon Choi, Seonghyang Sohn
    International Journal of Molecular Sciences.2024; 25(16): 8571.     CrossRef
  • Immuno-therapeutic and prophylactic potential of Trichinella spiralis antigens for inflammatory bowel diseases
    Majed H. Wakid, Walaa A. El Kholy, Muslimah N. Alsulami, Eman S. El-Wakil
    Food and Waterborne Parasitology.2024; 37: e00248.     CrossRef
  • Development of a novel complex inflammatory bowel disease mouse model: Reproducing human inflammatory bowel disease etiologies in mice
    Sun-Min Seo, Na-Won Kim, Eun-Seon Yoo, Ji-Hun Lee, Ah-Reum Kang, Han-Bi Jeong, Won-Yong Shim, Dong-Hyun Kim, Young-Jun Park, Kieun Bae, Kyong-Ah Yoon, Yang-Kyu Choi, Pradeep Dudeja
    PLOS ONE.2024; 19(11): e0311310.     CrossRef
  • Adiponectin deficiency prevents chronic colitis-associated colonic fibrosis via inhibiting CXCL13 production
    Haitao Xiao, Tianhang Xing, Miao Qiu, Guangtao Zhang, Gongli Yang, Wenke Chen, Die Hu, Deao Xue, Jiao Peng, Bin Du
    Journal of Advanced Research.2024;[Epub]     CrossRef
  • Gut Microbiome and Colorectal Cancer
    Tae-Geun Gweon
    The Korean Journal of Gastroenterology.2023; 82(2): 56.     CrossRef
  • Mitochondrial dysfunctions in T cells: focus on inflammatory bowel disease
    Hoyul Lee, Jae-Han Jeon, Eun Soo Kim
    Frontiers in Immunology.2023;[Epub]     CrossRef
  • 10,197 View
  • 443 Download
  • 26 Web of Science
  • 24 Crossref
Close layer
Original Articles
IBD
Risk of malignancies and chemopreventive effect of statin, metformin, and aspirin in Korean patients with ulcerative colitis: a nationwide population-based study
Eun Hye Oh, Ye-Jee Kim, Minju Kim, Seung Ha Park, Tae Oh Kim, Sang Hyoung Park
Intest Res 2025;23(2):129-143.   Published online November 9, 2023
DOI: https://doi.org/10.5217/ir.2023.00062
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Background/Aims
We investigated the incidences of overall and site-specific malignancies and chemopreventive effects of statin, metformin, and aspirin in patients with ulcerative colitis.
Methods
We collected data using the Health Insurance Review and Assessment claims database from January 2007 to April 2020.
Results
The overall malignancy risk among the 35,189 ulcerative colitis patients was similar to that of the general population (standardized incidence ratio, 0.94; 95% confidence interval, 0.88–1.00). In male patients, standardized incidence ratios were high for thyroid cancer and low for stomach cancer, colorectal cancer, liver cancer, and lung cancer. Concurrently, standard incidence ratios were high for liver cancer and central nervous system cancer in female patients. While 122 cases of colorectal cancer occurred in the study patients, the standardized incidence ratio was 0.83 (95% confidence interval, 0.69–0.99). Treatment for ulcerative colitis was not associated with an increased adjusted hazard ratio, while comorbidities increased it for all malignancies. Treatment for ulcerative colitis was associated with an increased adjusted hazard ratio, while comorbidities did not increase it for colorectal cancer. After adjusting for age, sex, comorbidities, and ulcerative colitis treatment, statins showed a dose-dependent chemopreventive effect for all malignancies (P=0.002), while metformin and aspirin did not show any.
Conclusions
In ulcerative colitis patients, standardized incidence ratios for all malignancies and colorectal cancer did not increase. Adjusted hazard ratios for all malignancies increased with comorbidities and those for colorectal cancer with ulcerative colitis treatment. Statins have a dose-dependent chemopreventive effect for all malignancies.

Citations

Citations to this article as recorded by  
  • Thyroid disorders and inflammatory bowel disease: an association present in adults but also in children and adolescents
    Valeria Calcaterra, Francesca Penagini, Virginia Rossi, Luisa Abbattista, Alice Bianchi, Massimiliano Turzi, Lucia Cococcioni, Gianvincenzo Zuccotti
    Frontiers in Endocrinology.2025;[Epub]     CrossRef
  • Does statin have a chemopreventive effect in patients with ulcerative colitis?
    Yoon Suk Jung
    Intestinal Research.2025; 23(2): 113.     CrossRef
  • 4,104 View
  • 478 Download
  • 3 Web of Science
  • 2 Crossref
Close layer
IBD
Predictive accuracy of fecal calprotectin for histologic remission in ulcerative colitis
Arshdeep Singh, Arshia Bhardwaj, Riya Sharma, Bhavjeet Kaur Kahlon, Ashvin Singh Dhaliwal, Dharmatma Singh, Simranjeet Kaur, Devanshi Jain, Namita Bansal, Ramit Mahajan, Kirandeep Kaur, Aminder Singh, Vikram Narang, Harpreet Kaur, Vandana Midha, Ajit Sood
Intest Res 2025;23(2):144-156.   Published online November 11, 2024
DOI: https://doi.org/10.5217/ir.2024.00068
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Background/Aims
Accurate assessment of disease activity is crucial for effective management and treatment of ulcerative colitis (UC). This study evaluated the correlation between clinical, endoscopic, and histologic measures of disease activity in UC.
Methods
Clinical, biochemical, endoscopic, and histologic disease activity was studied in 347 patients with UC. Agreements among various histologic classification systems, namely the Geboes Score (GS), Continuous GS, Nancy Index (NI), and Robarts Histopathology Index (RHI), were analyzed. The predictive accuracy of fecal calprotectin (FC) for endoscopic and histologic remission was assessed.
Results
We demonstrate a fair to moderate correlation between clinical, endoscopic, and histologic measures of disease activity in UC. There was a robust concordance among GS, Continuous GS, NI, and RHI in distinguishing between patients in histologic remission or activity. The NI detected 75% of patients who met the remission criteria according to the RHI, whereas the RHI identified all patients in remission as defined by the NI. FC levels below 150 μg/g had >70% accuracy in predicting endoscopic remission. FC levels below 150 μg/g showed ≥80% accuracy, and FC levels below 100 μg/g demonstrated ≥ 85% accuracy in predicting histologic remission, regardless of the scoring index applied. Elevated FC levels were associated with both acute and chronic inflammatory infiltrates in biopsy samples.
Conclusions
FC is a reliable predictor of histologic remission, with higher accuracy at lower thresholds. The GS, Continuous GS, NI, and RHI demonstrate comparable performance. FC could help stratify patients’ need for colonoscopy for the assessment of endoscopic and histologic remission.

Citations

Citations to this article as recorded by  
  • Beyond mucosal healing: fecal calprotectin and the path toward histologic remission in ulcerative colitis
    Yehyun Park
    Intestinal Research.2025; 23(2): 115.     CrossRef
  • Azathioprine or Tofacitinib as Maintenance Therapy in Corticosteroid‐Responsive Acute Severe Ulcerative Colitis
    Arshdeep Singh, Arshia Bhardwaj, Riya Sharma, Dharmatma Singh, Devanshi Jain, Namita Bansal, Gursimran Singh Kochhar, Vandana Midha, Ajit Sood
    Alimentary Pharmacology & Therapeutics.2025;[Epub]     CrossRef
  • Endo-histologic outcomes in patients with ulcerative colitis responding to tofacitinib
    Arshdeep Singh, Arshia Bhardwaj, Devanshi Jain, Riya Sharma, Dharmatma Singh, Ramit Mahajan, Kirandeep Kaur, Aminder Singh, Vikram Narang, Harpreet Kaur, Manavjot Singh, Pritish Gupta, Tanisha Sehgal, Vandana Midha, Ajit Sood
    Indian Journal of Gastroenterology.2025;[Epub]     CrossRef
  • 2,539 View
  • 175 Download
  • 2 Web of Science
  • 3 Crossref
Close layer
Statement
IBD
Management of Crohn’s disease in Taiwan: consensus guideline of the Taiwan Society of Inflammatory Bowel Disease updated in 2023
Jia-Feng Wu, Hsu-Heng Yen, Horng-Yuan Wang, Ting-An Chang, Chung-Hsin Chang, Chen-Wang Chang, Te-Hsin Chao, Jen-Wei Chou, Yenn-Hwei Chou, Chiao-Hsiung Chuang, Wen-Hung Hsu, Tzu-Chi Hsu, Tien-Yu Huang, Tsung-I Hung, Puo-Hsien Le, Chun-Che Lin, Chun-Chi Lin, Ching-Pin Lin, Jen-Kou Lin, Wei-Chen Lin, Yen-Hsuan Ni, Ming-Jium Shieh, I-Lun Shih, Chia-Tung Shun, Tzung-Jiun Tsai, Cheng-Yi Wang, Meng-Tzu Weng, Jau-Min Wong, Deng-Chyang Wu, Shu-Chen Wei
Intest Res 2024;22(3):250-285.   Published online July 29, 2024
DOI: https://doi.org/10.5217/ir.2024.00060
AbstractAbstract PDFPubReaderePub
Crohn’s disease (CD) is a chronic, fluctuating inflammatory condition that primarily affects the gastrointestinal tract. Although the incidence of CD in Taiwan is lower than that in Western countries, the severity of CD presentation appears to be similar between Asia and the West. This observation indicates the urgency for devising revised guidelines tailored to the unique reimbursement system, and patient requirements in Taiwan. The core objectives of these updated guidelines include the updated treatment choices and the integration of the treat-to-target strategy into CD management, promoting the achievement of deep remission to mitigate complications and enhance the overall quality of life. Given the diversity in disease prevalence, severity, insurance policies, and access to medical treatments in Taiwan, a customized approach is imperative for formulating these guidelines. Such tailored strategies ensure that international standards are not only adapted but also optimized to local contexts. Since the inception of its initial guidelines in 2017, the Taiwan Society of Inflammatory Bowel Disease (TSIBD) has acknowledged the importance of continuous revisions for incorporating new therapeutic options and evolving disease management practices. The latest update leverages international standards and recent research findings focused on practical implementation within the Taiwanese healthcare system.

Citations

Citations to this article as recorded by  
  • Annual Therapeutic Drug Monitoring in Patients with Inflammatory Bowel Disease During Infliximab Maintenance Therapy: Balancing Efficacy with Risk of Pharmacokinetic Failure
    Yujin Lim, Boram Park, Kyeongman Jeon, Ok Soon Jeong, Eun Ran Kim, Young-Ho Kim, Dong Kyung Chang, Sung Noh Hong
    Digestive Diseases and Sciences.2025;[Epub]     CrossRef
  • Impact of Obesity on the Long-Term Outcomes of Advanced Therapies in IBD: A Real-World Study in Taiwan
    Wei-Chun Hsu, Shih-Hua Lin, Chia-Jung Kuo, Horng-Yih Chiu, Chien-Ming Chen, Ming-Yao Su, Cheng-Tang Chiu, Chen-Wang Chang, Tien-Yu Huang, Yu-Bin Pan, Puo-Hsien Le
    Journal of Inflammation Research.2025; Volume 18: 7139.     CrossRef
  • 5,700 View
  • 247 Download
  • 2 Web of Science
  • 2 Crossref
Close layer
Reviews
IBD
Helminths in alternative therapeutics of inflammatory bowel disease
Himani Pandey, Daryl W. T. Tang, Sunny H. Wong, Devi Lal
Intest Res 2025;23(1):8-22.   Published online January 12, 2024
DOI: https://doi.org/10.5217/ir.2023.00059
AbstractAbstract PDFPubReaderePub
Inflammatory bowel disease (IBD), which includes Crohn’s disease and ulcerative colitis, is a nonspecific chronic inflammation of the gastrointestinal tract. Despite recent advances in therapeutics and newer management strategies, IBD largely remains untreatable. Helminth therapy is a promising alternative therapeutic for IBD that has gained some attention in the last two decades. Helminths have immunomodulatory effects and can alter the gut microbiota. The immunomodulatory effects include a strong Th2 immune response, T-regulatory cell response, and the production of regulatory cytokines. Although concrete evidence regarding the efficacy of helminth therapy in IBD is lacking, clinical studies and studies done in animal models have shown some promise. Most clinical studies have shown that helminth therapy is safe and easily tolerable. Extensive work has been done on the whipworm Trichuris, but other helminths, including Schistosoma, Trichinella, Heligmosomoides, and Ancylostoma, have also been explored for pre-clinical and animal studies. This review article summarizes the potential of helminth therapy as an alternative therapeutic or an adjuvant to the existing therapeutic procedures for IBD treatment.

Citations

Citations to this article as recorded by  
  • Generation of Immune Modulating Small Metabolites—Metabokines—By Adult Schistosomes
    Patrick J. Skelly, Akram A. Da’dara
    Pathogens.2025; 14(6): 526.     CrossRef
  • An experimental study of the dual modulation of the colchicine-induced rat model of Alzheimer’s disease by superparamagnetic iron oxide nanoparticles (SPIONs) and the soluble product of Dipylidium caninum adult worm
    Amal M. Elsharkawy, Faika Hassanein, Samia S. Abouelkheir, Inas M. Masoud, Wael Felefel, Inas E. Darwish, Abdelfattah Selim
    PLOS One.2025; 20(6): e0324191.     CrossRef
  • 6,848 View
  • 390 Download
  • 2 Web of Science
  • 2 Crossref
Close layer
IBD
Gut microbiota in pathophysiology, diagnosis, and therapeutics of inflammatory bowel disease
Himani Pandey, Dheeraj Jain, Daryl W. T. Tang, Sunny H. Wong, Devi Lal
Intest Res 2024;22(1):15-43.   Published online November 8, 2023
DOI: https://doi.org/10.5217/ir.2023.00080
AbstractAbstract PDFPubReaderePub
Inflammatory bowel disease (IBD) is a multifactorial disease, which is thought to be an interplay between genetic, environment, microbiota, and immune-mediated factors. Dysbiosis in the gut microbial composition, caused by antibiotics and diet, is closely related to the initiation and progression of IBD. Differences in gut microbiota composition between IBD patients and healthy individuals have been found, with reduced biodiversity of commensal microbes and colonization of opportunistic microbes in IBD patients. Gut microbiota can, therefore, potentially be used for diagnosing and prognosticating IBD, and predicting its treatment response. Currently, there are no curative therapies for IBD. Microbiota-based interventions, including probiotics, prebiotics, synbiotics, and fecal microbiota transplantation, have been recognized as promising therapeutic strategies. Clinical studies and studies done in animal models have provided sufficient evidence that microbiota-based interventions may improve inflammation, the remission rate, and microscopic aspects of IBD. Further studies are required to better understand the mechanisms of action of such interventions. This will help in enhancing their effectiveness and developing personalized therapies. The present review summarizes the relationship between gut microbiota and IBD immunopathogenesis. It also discusses the use of gut microbiota as a noninvasive biomarker and potential therapeutic option.

Citations

Citations to this article as recorded by  
  • Chitosan and its derivatives: A novel approach to gut microbiota modulation and immune system enhancement
    Great Iruoghene Edo, Alice Njolke Mafe, Ali B.M. Ali, Patrick Othuke Akpoghelie, Emad Yousif, Jesse Innocent Apameio, Endurance Fegor Isoje, Ufuoma Augustina Igbuku, Yasal Garba, Arthur Efeoghene Athan Essaghah, Dina S. Ahmed, Huzaifa Umar, Dilber Uzun Oz
    International Journal of Biological Macromolecules.2025; 289: 138633.     CrossRef
  • Advances in bio-polymer coatings for probiotic microencapsulation: chitosan and beyond for enhanced stability and controlled release
    Great Iruoghene Edo, Alice Njolke Mafe, Nawar. F. Razooqi, Ebuka Chukwuma Umelo, Tayser Sumer Gaaz, Endurance Fegor Isoje, Ufuoma Augustina Igbuku, Patrick Othuke Akpoghelie, Rapheal Ajiri Opiti, Arthur Efeoghene Athan Essaghah, Dina S. Ahmed, Huzaifa Uma
    Designed Monomers and Polymers.2025; 28(1): 1.     CrossRef
  • Helminths in alternative therapeutics of inflammatory bowel disease
    Himani Pandey, Daryl W. T. Tang, Sunny H. Wong, Devi Lal
    Intestinal Research.2025; 23(1): 8.     CrossRef
  • Protective effect of low-dose lactulose in dextran sulfate sodium induced ulcerative colitis model of rats
    Min Cui, Wei-Ming Yang, Ping Yao
    Scientific Reports.2025;[Epub]     CrossRef
  • Unraveling the Role of Fusobacterium nucleatum in Colorectal Cancer: Molecular Mechanisms and Pathogenic Insights
    Linda Galasso, Fabrizio Termite, Irene Mignini, Giorgio Esposto, Raffaele Borriello, Federica Vitale, Alberto Nicoletti, Mattia Paratore, Maria Elena Ainora, Antonio Gasbarrini, Maria Assunta Zocco
    Cancers.2025; 17(3): 368.     CrossRef
  • Lactobacillus vaginalis alleviates DSS induced colitis by regulating the gut microbiota and increasing the production of 3-indoleacrylic acid
    Zhuoya Wang, Tian Liu, Li Liu, Jian Xie, Furui Tang, Yimin Pi, Yuchun Zhong, Zhidong He, Wenming Zhang, Cihua Zheng
    Pharmacological Research.2025; 213: 107663.     CrossRef
  • Therapeutic systems based on natural gut microbiota modulators: the latest advances in the treatment of inflammatory bowel disease
    Zelin Guan, Peilin Niu, Qichao Tan, Yidong Wang, Shujing Deng, Danyang Wang, Kai Dong, Jianfeng Xing, Cuiyu You
    Materials Advances.2025; 6(5): 1578.     CrossRef
  • Metabolic musculoskeletal disorders in patients with inflammatory bowel disease
    Young Joo Yang, Seong Ran Jeon
    The Korean Journal of Internal Medicine.2025; 40(2): 181.     CrossRef
  • Photobiomodulation and the oral-gut microbiome axis: therapeutic potential and challenges
    Neda Hakimiha, Somayeh Jahani Sherafat, E-Liisa Laakso, Reza Fekrazad
    Frontiers in Medicine.2025;[Epub]     CrossRef
  • Dinamiche del microbioma: dai cambiamenti nel corso della vita alla disbiosi nelle patologie tumorali
    Marcella NUNZIATO
    Biochimica Clinica.2025;[Epub]     CrossRef
  • Gut microbiota — bidirectional modulator: role in inflammatory bowel disease and colorectal cancer
    Xilun Cui, Changfeng Li, Jing Zhong, Yuanda Liu, Pengtuo Xiao, Chang Liu, Mengwei Zhao, Wei Yang
    Frontiers in Immunology.2025;[Epub]     CrossRef
  • Metabolic Disorders and Inflammatory Bowel Diseases
    Hye Kyung Hyun, Jae Hee Cheon
    Gut and Liver.2025; 19(3): 307.     CrossRef
  • Incidence, Risk Factors, and Outcomes of Chronic Antibiotic-Refractory Pouchitis in Korean Patients with Ulcerative Colitis
    Ji Eun Baek, Jung-Bin Park, June Hwa Bae, Min Hyun Kim, Seung Wook Hong, Sung Wook Hwang, Jong Lyul Lee, Yong Sik Yoon, Dong-Hoon Yang, Byong Duk Ye, Jeong-Sik Byeon, Seung-Jae Myung, Chang Sik Yu, Suk-Kyun Yang, Sang Hyoung Park
    Gut and Liver.2025; 19(3): 388.     CrossRef
  • Personalized Microbiome Modulation to Improve Clinical Outcomes in Pediatric Inflammatory Bowel Disease: A Multi-Omics and Interventional Approach
    Adrian Goldiș, Radu Dragomir, Marina Adriana Mercioni, Christian Goldiș, Diana Sirca, Ileana Enătescu, Laura Olariu, Oana Belei
    Microorganisms.2025; 13(5): 1047.     CrossRef
  • Engineering artificial microbial consortia for personalized gut microbiome modulation and disease treatment
    Timoth Mkilima
    Annals of the New York Academy of Sciences.2025; 1548(1): 29.     CrossRef
  • Gastric Cancer and Microbiota: Exploring the Microbiome’s Role in Carcinogenesis and Treatment Strategies
    Daniela-Cornelia Lazăr, Sorin-Dan Chiriac, George-Andrei Drăghici, Elena-Alina Moacă, Alexandra Corina Faur, Mihaela-Flavia Avram, Vladiana-Romina Turi, Mihaela-Roxana Nicolin, Adrian Goldiș, Matin Asad Salehi, Radu Jipa
    Life.2025; 15(7): 999.     CrossRef
  • TMAO and the gut microbiome: implications for the CVD-CKD-IBD axis
    Si Hyoung Kim, Mi Young Yoon, Sang Sun Yoon
    Annals of Medicine.2025;[Epub]     CrossRef
  • Gut microbiota in non-alcoholic fatty liver disease: Pathophysiology, diagnosis, and therapeutics
    Himani Pandey, Prabudh Goel, Varunvenkat M Srinivasan, Daryl W T Tang, Sunny H Wong, Devi Lal
    World Journal of Hepatology.2025;[Epub]     CrossRef
  • MH002, a Novel Butyrate-Producing Consortium of Six Commensal Bacterial Strains Has Immune-Modulatory and Mucosal-Healing Properties
    Iris Pinheiro, Selin Bolca, Lien Van den Bossche, Wiebe Vanhove, Sara Van Ryckeghem, Davide Gottardi, Debby Laukens, Sam Possemiers
    International Journal of Molecular Sciences.2025; 26(13): 6167.     CrossRef
  • Editorial: Environments-pathogens-the gut microbiota and host diseases
    Jinbo Xiong, Zunji Shi
    Frontiers in Microbiology.2024;[Epub]     CrossRef
  • Endoplasmic reticulum stress: A possible connection between intestinal inflammation and neurodegenerative disorders
    Giorgio Vivacqua, Romina Mancinelli, Stefano Leone, Rosa Vaccaro, Ludovica Garro, Simone Carotti, Ludovica Ceci, Paolo Onori, Luigi Pannarale, Antonio Franchitto, Eugenio Gaudio, Arianna Casini
    Neurogastroenterology & Motility.2024;[Epub]     CrossRef
  • Advances in Precision Medicine Approaches for Colorectal Cancer: From Molecular Profiling to Targeted Therapies
    Neelakanta Sarvashiva Kiran, Chandrashekar Yashaswini, Rahul Maheshwari, Sankha Bhattacharya, Bhupendra G. Prajapati
    ACS Pharmacology & Translational Science.2024; 7(4): 967.     CrossRef
  • Healing from Within: How Gut Microbiota Predicts IBD Treatment Success—A Systematic Review
    Luana Alexandrescu, Alina Doina Nicoara, Doina Ecaterina Tofolean, Alexandra Herlo, Andreea Nelson Twakor, Cristina Tocia, Anamaria Trandafir, Andrei Dumitru, Eugen Dumitru, Cristian Florentin Aftenie, Ionela Preotesoiu, Elena Dina, Ioan Tiberiu Tofolean
    International Journal of Molecular Sciences.2024; 25(15): 8451.     CrossRef
  • Effect of Mutant and Engineered High-Acetate-Producing Saccharomyces cerevisiae var. boulardii Strains in Dextran Sodium Sulphate-Induced Colitis
    Sara Deleu, Inge Jacobs, Jorge F. Vazquez Castellanos, Sare Verstockt, Bruna Trindade de Carvalho, Ana Subotić, Bram Verstockt, Kaline Arnauts, Lowie Deprez, Eva Vissers, Matthias Lenfant, Greet Vandermeulen, Gert De Hertogh, Kristin Verbeke, Gianluca Mat
    Nutrients.2024; 16(16): 2668.     CrossRef
  • The emerging role of the gut microbiota and its application in inflammatory bowel disease
    Xiu Wang, Jianhua Peng, Peipei Cai, Yuxuan Xia, Chengxue Yi, Anquan Shang, Francis Atim Akanyibah, Fei Mao
    Biomedicine & Pharmacotherapy.2024; 179: 117302.     CrossRef
  • Bifidogenic Effect of Human Milk Oligosaccharides on Pediatric IBD Fecal Microbiota
    Nize Otaru, Danica Bajic, Pieter Van den Abbeele, Saskia Vande Velde, Stephanie Van Biervliet, Robert E. Steinert, Ateequr Rehman
    Microorganisms.2024; 12(10): 1977.     CrossRef
  • Analysis of the Preventive Effect of Lonicera caerulea Pomace and Its Isolated Components on Colitis in Mice Based on Gut Microbiota and Serum Metabolomics
    Zinuo Zhou, Xinwen Huang, Baixi Zhang
    Antioxidants.2024; 13(12): 1478.     CrossRef
  • Gut microbiota mediated T cells regulation and autoimmune diseases
    Nabeel Khalid Bhutta, Xiujin Xu, Cuiqin Jian, Yifan Wang, Yi Liu, Jinlyu Sun, Bingnan Han, Shandong Wu, Ansar Javeed
    Frontiers in Microbiology.2024;[Epub]     CrossRef
  • Reduced gut microbiota diversity in ulcerative colitis patients with latent tuberculosis infection during vedolizumab therapy: insights on prophylactic anti-tuberculosis effects
    Yibing Hu, Zhenping Wu, Xiaoyun Yang, Jin Ding, Qunying Wang, Hao Fang, Lujian Zhu, Minli Hu
    BMC Microbiology.2024;[Epub]     CrossRef
  • 12,839 View
  • 506 Download
  • 29 Web of Science
  • 29 Crossref
Close layer
Original Article
IBD
Early resolution of bowel urgency by budesonide foam enema results in improved quality of life in patients with ulcerative colitis: a multicenter prospective observational study
Taku Kobayashi, Kei Moriya, Toshimitsu Fujii, Shigeki Bamba, Shinichiro Shinzaki, Akihiro Yamada, Takashi Hisabe, Shintaro Sagami, Shuji Hibiya, Takahiro Amano, Noritaka Takatsu, Katsutoshi Inagaki, Ken-ichi Iwayama, Toshifumi Hibi
Intest Res 2025;23(2):157-169.   Published online July 15, 2024
DOI: https://doi.org/10.5217/ir.2024.00005
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Background/Aims
Bowel urgency is an important symptom for quality of life determination in patients with ulcerative colitis (UC). Few clinical studies have focused on bowel urgency as an efficacy endpoint. Budesonide foam enema has shown efficacy for clinical and endoscopic improvement in mild-to-moderate UC. We evaluated the improvement of clinical symptoms (bowel urgency), safety, and treatment impact of twice-daily budesonide foam enema on the quality of life in patients with UC.
Methods
This open-label, multicenter, prospective observational study comprised a 4-week observation period assessing the effectiveness and safety of twice-daily budesonide foam enema. Mild-to-moderate UC patients who had bowel urgency were included. Patients collected data daily in an electronic patient-reported outcome system or logbooks. The primary endpoint was the rate of resolution of bowel urgency at the end of the 4-week observation period. The rate of bowel incontinence was also assessed.
Results
Sixty-one patients were enrolled. Of patients with a final evaluation, the rate of resolution of bowel urgency was 58.5% (31/53; 95% confidence interval, 44.1%–71.9%). Bowel urgency decreased over time, with a significant difference observed on day 7 versus day 0. Bowel incontinence showed a decreasing trend from day 5, with a significant difference confirmed on day 12 versus day 0. The clinical remission rate was 64.4% (38/59; 95% confidence interval, 50.9%–76.4%). One adverse event not related to budesonide rectal foam occurred.
Conclusions
The findings suggest that bowel urgency can be improved early with twice-daily budesonide foam enema. No new safety signals were observed.
  • 3,587 View
  • 300 Download
Close layer
Editorial
IBD
Does statin have a chemopreventive effect in patients with ulcerative colitis?
Yoon Suk Jung
Intest Res 2025;23(2):113-114.   Published online April 29, 2025
DOI: https://doi.org/10.5217/ir.2025.00048
PDFPubReaderePub
  • 432 View
  • 31 Download
Close layer
Original Article
IBD
Leucine-rich alpha-2 glycoprotein is useful in predicting clinical relapse in patients with Crohn’s disease during biological remission
Naohiro Nakamura, Yusuke Honzawa, Yuka Ito, Yasuki Sano, Naoto Yagi, Sanshiro Kobayashi, Mamiko Aoi, Takashi Tomiyama, Tomomitsu Tahara, Norimasa Fukata, Toshiro Fukui, Makoto Naganuma
Intest Res 2025;23(2):170-181.   Published online August 19, 2024
DOI: https://doi.org/10.5217/ir.2024.00042
AbstractAbstract PDFPubReaderePub
Background/Aims
Serum leucine-rich alpha-2 glycoprotein (LRG) is a potential biomarker of Crohn’s disease (CD). This study aimed to evaluate the usefulness of LRG in predicting clinical relapse in patients in remission with CD.
Methods
This retrospective observational study assessed the relationships among patient-reported outcome (PRO2), LRG, and other blood markers. The influence of LRG on clinical relapse was assessed in patients in remission with CD.
Results
Data of 94 patients tested for LRG between January 2021 and May 2023 were collected. LRG level did not correlate with PRO2 score (ρ = 0.06); however, it strongly correlated with C-reactive protein (CRP) level (r=0.79) and serum albumin level (r=–0.70). Among 69 patients in clinical remission, relapse occurred in 22 patients (31.9%). In the context of predicting relapse, LRG showed the highest area under the curve, followed by CRP level, platelet count, and albumin level. Multivariate analysis revealed that only LRG (P= 0.02) was an independent factor for predicting clinical remission. The cumulative non-relapse rate was significantly higher in patients with LRG < 13.8 μg/mL than in patients in remission with LRG ≥ 13.8 μg/mL and normal CRP level (P= 0.002) or normal albumin level (P= 0.001). Cumulative non-relapse rate was also higher in patients with LRG < 13.8 μg/mL compared to those with LRG ≥ 13.8 μg/mL in patients with L3 or B2+B3 of Montreal calcification.
Conclusions
LRG is useful in predicting clinical relapse in patients with CD during biological remission. LRG is a useful biomarker for predicting prognosis, even in patients with intestinal stenosis, or previous/present fistulas.
  • 2,423 View
  • 183 Download
Close layer
Editorial
IBD
Beyond mucosal healing: fecal calprotectin and the path toward histologic remission in ulcerative colitis
Yehyun Park
Intest Res 2025;23(2):115-116.   Published online April 29, 2025
DOI: https://doi.org/10.5217/ir.2025.00056
PDFPubReaderePub
  • 477 View
  • 28 Download
Close layer
Original Article
IBD
Histologic healing and clinical outcomes in ulcerative colitis
Raymond Fueng-Hin Liang, Huiyu Lin, Cora Yuk-Ping Chau, Wee Chian Lim
Intest Res 2025;23(2):182-192.   Published online September 19, 2024
DOI: https://doi.org/10.5217/ir.2024.00058
AbstractAbstract PDFPubReaderePub
Background/Aims
Growing evidence suggests histologic healing (HH) improves clinical outcomes in ulcerative colitis (UC) patients beyond endoscopic healing (EH). We hypothesize that HH is associated with better clinical outcomes in Asian UC patients, for whom data is lacking.
Methods
We performed a retrospective study of UC patients in clinical remission (CR) with a follow-up colonoscopy and minimum 1-year follow-up post-colonoscopy. Primary outcome was clinical relapse (CRL), defined as either a Simple Clinical Colitis Activity Index score of > 2, medication escalation, hospitalization or colectomy. Predictors of CRL and HH were assessed.
Results
One hundred patients were included with a median follow-up of 22 months. At index colonoscopy, 80 patients were in EH. On follow-up, 41 patients experienced CRL. Of 80 patients in EH, 34 (42.5%) had persistent histologic activity (Nancy Index ≥ 2) and 29 (36.3%) relapsed during the follow-up period. Amongst patients in CR and EH, those with HH had lower CRL rate (26.1% vs. 50.0%, P= 0.028) and longer CRL-free survival (mean 46.1 months vs. 31.5 months, P= 0.015) than those with persistent histologic activity. On bivariable analysis of 100 patients in CR, HH, and Mayo endoscopic score (MES) of 0 were significantly associated with lower risk of CRL. On multivariable analysis, only MES 0 remained predictive of lower CRL risk.
Conclusions
Above and beyond CR and EH, achieving HH improves clinical outcomes in Asian UC patients. However, HH may not confer incremental benefit if MES 0 has been achieved. Further prospective studies evaluating the benefit of histologically guided therapeutic decisions are needed.
  • 2,154 View
  • 153 Download
Close layer
Review
IBD
First aid with color atlas for the use of intestinal ultrasound for inflammatory bowel disease in daily clinical practice
Jun Miyoshi, Hiromu Morikubo, Hiromi Yonezawa, Hideaki Mori, Tadakazu Hisamatsu
Intest Res 2023;21(2):177-188.   Published online April 28, 2023
DOI: https://doi.org/10.5217/ir.2023.00003
AbstractAbstract PDFPubReaderePub
Intestinal ultrasound (IUS) is a promising modality for the management of inflammatory bowel disease (IBD) and has the potential to particularly contribute in monitoring disease activity, an advantage crucial for optimizing the therapeutic strategy. While many IBD physicians appreciate and are interested in the use of IUS for IBD, currently only a limited number of facilities can employ this examination in daily clinical practice. A lack of guidance is one of the major barriers to introducing this procedure. Standardized protocols and assessment criteria are needed such that IUS for IBD can be considered a feasible, reliable examination in clinical practice, and multicenter clinical studies can be conducted for further clinical evidence of the application of IUS in IBD for best patient care. In this article, we provide an overview of how to start IUS for IBD and introduce basic procedures. Furthermore, IUS images from our practice are provided as a color atlas for understanding sonographic findings and scoring systems. We anticipate this “first aid” article will be helpful to promote IUS for IBD in daily practice.

Citations

Citations to this article as recorded by  
  • Determination of optimal cutoff value of ulcerative colitis intestinal ultrasound index to estimate endoscopic improvement in ulcerative colitis
    Haruka Komatsu, Hiromu Morikubo, Yoko Kimura, Chihiro Moue, Hiromi Yonezawa, Minoru Matsuura, Jun Miyoshi, Tadakazu Hisamatsu
    Journal of Gastroenterology.2025; 60(2): 166.     CrossRef
  • Bildgebung bei chronisch-entzündlichen Darmerkrankungen
    Christoph F. Dietrich, Kathleen Möller
    Die Innere Medizin.2025; 66(1): 40.     CrossRef
  • Recent Advances in Molecular Targeted Therapy for Inflammatory Bowel Disease
    Tadakazu Hisamatsu, Jun Miyoshi, Minoru Matsuura
    Internal Medicine.2025;[Epub]     CrossRef
  • A combination of bowel wall thickness and submucosa index is useful for estimating endoscopic improvement in ulcerative colitis: external validation of the Kyorin Ultrasound Criterion
    Haruka Komatsu, Hiromu Morikubo, Yoko Kimura, Chihiro Moue, Hiromi Yonezawa, Minoru Matsuura, Jun Miyoshi, Tadakazu Hisamatsu
    Journal of Gastroenterology.2024; 59(3): 209.     CrossRef
  • Early Sonographic Improvement Predicts Clinical Remission and Mucosal Healing With Molecular-Targeted Drugs in Ulcerative Colitis
    Yoko Kimura, Jun Miyoshi, Hiromu Morikubo, Haruka Komatsu, Chihiro Moue, Hiromi Yonezawa, Minoru Matsuura, Tadakazu Hisamatsu
    Gastro Hep Advances.2024; 3(6): 703.     CrossRef
  • IBD barriers across the continents – East Asia
    Joyce Wing Yan Mak, Agnes Hiu Yan Ho, Siew Chien Ng
    Therapeutic Advances in Gastroenterology.2023;[Epub]     CrossRef
  • 5,604 View
  • 382 Download
  • 6 Web of Science
  • 6 Crossref
Close layer
Original Article
Microbiota
Exploring the link between celiac disease and obesity: a potential role of gut microbiome
Sunaina Addanki, Anastasia Mashukova, Arkene Levy
Intest Res 2025;23(2):193-201.   Published online November 8, 2024
DOI: https://doi.org/10.5217/ir.2024.00049
AbstractAbstract PDFPubReaderePub
Background/Aims
In today’s age, celiac disease (CD) is no longer solely characterized by chronic diarrhea in a malnourished child. Obesity is gradually being acknowledged as part of CD’s clinical course. Both conditions have been linked to alterations of gut microbiome. Given the difficulty of strict gluten-free diet adherence, there is a need for less restrictive adjunctive therapies. We aimed to investigate the prevalence of obesity in patients diagnosed with CD with the goal of developing new therapeutic approaches.
Methods
Baseline data from the National Institute of Health’s All of Us Research Program, was used to evaluate the relationship between CD and obesity. A retrospective cohort study was conducted where groups of individuals with CD and without CD were matched by age range and health surveys. Statistical analysis with odds ratios (OR) with 95% confidence intervals (CI) were reported.
Results
The prevalence of obesity was 32.6% in the CD group compared to 18.4% in the control group (OR, 2.111; 95% CI, 1.914–2.328; P< 0.0001). Women accounted for a greater population of patients with CD and obesity. The largest percentage of patients with CD and obesity were older than 65 years. The highest percentage of individuals in both the experimental and control groups were white, followed by African Americans.
Conclusions
Our data shows a significant association between CD and increased prevalence of obesity. These results warrant further investigation into microbial changes and dietary exposures that affect the pathogenesis of both diseases.

Citations

Citations to this article as recorded by  
  • Celiac Disease and Metabolic Diseases: A Review of Emerging Connections
    Deirdre Reidy, Christopher Cao, Alexandra Rosenstock, Melissa Stoffels, Sonal Kumar, Haley M. Zylberberg
    Current Treatment Options in Gastroenterology.2025;[Epub]     CrossRef
  • 2,277 View
  • 153 Download
  • 1 Crossref
Close layer
Reviews
Functional disorder
Diagnostic strategy of irritable bowel syndrome: a low- and middle-income country perspective
Amal Arifi Hidayat, Langgeng Agung Waskito, Titong Sugihartono, Hafeza Aftab, Yudith Annisa Ayu Rezkitha, Ratha-korn Vilaichone, Muhammad Miftahussurur
Intest Res 2024;22(3):286-296.   Published online March 26, 2024
DOI: https://doi.org/10.5217/ir.2023.00199
AbstractAbstract PDFPubReaderePub
Irritable bowel syndrome (IBS) is a highly prevalent gastrointestinal disorder associated with substantial impairment which considerably burdens healthcare systems worldwide. Research on IBS has largely been conducted in high-income countries posing barriers to the application of diagnostic strategies in low- and middle-income countries (LMICs) due to differences in disease characteristics, healthcare resources, and socioeconomic factors. This review discusses the diagnostic issues associated with LMICs. We present a concise overview of the relevant approaches and propose a diagnostic strategy based on the latest evidence. A positive diagnostic strategy that relies on appropriate symptom-based criteria is crucial within the diagnostic framework. A combination of complete blood count, fecal occult blood test, and complete stool test may reliably identify individuals with suspected IBS who are more likely to have organic diseases, thus justifying the necessity for a colonoscopy. Eventually, we developed a diagnostic algorithm based on a limited setting perspective that summarizes the available evidence and may be applied in LMICs.

Citations

Citations to this article as recorded by  
  • 2025 Seoul Consensus on Clinical Practice Guidelines for Irritable Bowel Syndrome
    Yonghoon Choi, Young Hoon Youn, Seung Joo Kang, Jeong Eun Shin, Young Sin Cho, Yoon Suk Jung, Seung Yong Shin, Cheal Wung Huh, Yoo Jin Lee, Hoon Sup Koo, Kwangwoo Nam, Hong Sub Lee, Dong Hyun Kim, Ye Hyun Park, Min Cheol Kim, Hyo Yeop Song, Sung-Hoon Yoon
    Journal of Neurogastroenterology and Motility.2025; 31(2): 133.     CrossRef
  • 7,173 View
  • 299 Download
  • 1 Web of Science
  • 1 Crossref
Close layer
IBD
The practice of fecal microbiota transplantation in inflammatory bowel disease
Umang Arora, Saurabh Kedia, Vineet Ahuja
Intest Res 2024;22(1):44-64.   Published online November 21, 2023
DOI: https://doi.org/10.5217/ir.2023.00085
AbstractAbstract PDFPubReaderePub
Current evidence posits a central role for gut microbiota and the metabolome in the pathogenesis and progression of inflammatory bowel disease (IBD). Fecal microbiota transplantation (FMT) has been established as a means to manipulate this microbiome safely and sustainably. Several aspects of the technical improvement including pretreatment with antibiotics, use of frozen stool samples as well as short donor-to-recipient time are proposed to improve its response rates. Its efficacy in ulcerative colitis has been proven in clinical trials while data is emerging for Crohn’s disease. This review describes briefly the biology behind FMT, the available evidence for its use in IBD, and the host, recipient and procedural factors which determine the clinical outcomes.

Citations

Citations to this article as recorded by  
  • Advances in Fecal Microbiota Transplantation for Gut Dysbiosis‐Related Diseases
    Shuna Hou, Jiachen Yu, Yongshuang Li, Duoyi Zhao, Zhiyu Zhang
    Advanced Science.2025;[Epub]     CrossRef
  • Gut Microbial Targets in Inflammatory Bowel Disease: Current Position and Future Developments
    Naveen Sivakumar, Ashwin Krishnamoorthy, Harshita Ryali, Ramesh P. Arasaradnam
    Biomedicines.2025; 13(3): 716.     CrossRef
  • Medical management of acute severe ulcerative colitis in the hospitalized patient
    Loren G Rabinowitz, Ajay Gade, Joseph D. Feuerstein
    Expert Review of Gastroenterology & Hepatology.2025; 19(5): 467.     CrossRef
  • Incidence, Risk Factors, and Outcomes of Chronic Antibiotic-Refractory Pouchitis in Korean Patients with Ulcerative Colitis
    Ji Eun Baek, Jung-Bin Park, June Hwa Bae, Min Hyun Kim, Seung Wook Hong, Sung Wook Hwang, Jong Lyul Lee, Yong Sik Yoon, Dong-Hoon Yang, Byong Duk Ye, Jeong-Sik Byeon, Seung-Jae Myung, Chang Sik Yu, Suk-Kyun Yang, Sang Hyoung Park
    Gut and Liver.2025; 19(3): 388.     CrossRef
  • Biomaterial-based therapeutic strategies for inflammatory bowel disease
    Wei Sun, Zhibo Li, Xiaohao Zhang, Qiang Luo, Lijuan Wei, Chunsheng Xiao
    Biomaterials.2025; : 123462.     CrossRef
  • The effect of fecal microbiota transplantation on levels of tryptophan metabolites in intestine and serum of gnotobiotic mice
    O.P. Shatova, A.V. Shestopalov, E.Yu. Zlatnik, I.A. Novikova, A.S. Goncharova, A.Yu. Maksimov
    Biomeditsinskaya Khimiya.2025; 71(3): 209.     CrossRef
  • Perception of fecal microbiota transplantation in patients with ulcerative colitis in Korea: a KASID multicenter study
    Jebyung Park, Sung Noh Hong, Hong Sub Lee, Jongbeom Shin, Eun Hye Oh, Kwangwoo Nam, Gyeol Seong, Hyun Gun Kim, Jin-Oh Kim, Seong Ran Jeon
    The Korean Journal of Internal Medicine.2024; 39(5): 783.     CrossRef
  • Microbiome-based therapeutics for Parkinson's disease
    Adam M. Hamilton, Ian N. Krout, Alexandria C. White, Timothy R. Sampson
    Neurotherapeutics.2024; 21(6): e00462.     CrossRef
  • 8,354 View
  • 369 Download
  • 8 Crossref
Close layer
Original Article
Endoscopy
Newly designed flared-end covered versus uncovered self-expandable metallic stents for palliation of malignant colorectal obstruction: a randomized, prospective study
Soo Jung Park, Yehyun Park, Hyun Jung Lee, Jae Jun Park, Jae Hee Cheon, Won Ho Kim, Tae Il Kim
Intest Res 2025;23(2):202-212.   Published online February 24, 2025
DOI: https://doi.org/10.5217/ir.2024.00135
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Background/Aims
Self-expandable metallic stents (SEMSs) are widely used as palliative or bridge to surgery treatments in patients with malignant colorectal obstruction (MCO). Stent occlusion is more common with uncovered stents, but stent migration is more common with covered stents. Our purpose was to compare the efficacy and safety of a newly designed covered SEMS with an uncovered proximal flared end (CSEMS-UPF) with that of the conventional uncovered SEMS (UCSEMS) in the treatment of MCO.
Methods
This prospective randomized trial was conducted at a tertiary-care academic hospital. We enrolled 87 patients with stage 4 cancer and MCO: colorectal cancer in 60 patients and extracolonic cancer in 27 patients. Insertion of UCSEMS was randomly assigned to 43 patients, and 44 patients received the CSEMS-UPF. The primary outcome was the duration of stent patency after successful placement. The secondary outcomes were the number of patients with technical and clinical success and early and late complications from the stent insertion.
Results
The median patency of the stent did not differ between the UCSEMS and CSEMS-UPF groups (484 [231–737] days vs. 216 [66–366] days, P= 0.242). The technical and clinical success rates did not differ significantly between the groups, either (100.0% vs. 93.2%, respectively, P= 0.241; 100.0% vs. 92.7%, respectively, P= 0.112), nor did the early (n = 2 [4.7%] vs. n = 4 [9.8%], P> 0.999) or late (n = 12 [27.9%] vs. n = 15 [36.6%], P> 0.999) stent complication rates differ between the groups.
Conclusions
The UCSEMS and newly developed CSEMS-UPF are similarly effective treatments for MCO, with no differences in the stent migration or occlusion rates (Clinical trial registration number: NCT02640781).
  • 1,140 View
  • 115 Download
Close layer
Case Report
IBD
Combined eosinophilic gastroenteritis and ulcerative colitis successfully treated by vedolizumab: a case report
Hironobu Takedomi, Kayoko Fukuda, Suma Inoue, Nanae Tsuruoka, Yasuhisa Sakata, Shigehisa Aoki, Motohiro Esaki
Intest Res 2025;23(1):107-111.   Published online August 29, 2024
DOI: https://doi.org/10.5217/ir.2024.00013
AbstractAbstract PDFPubReaderePub
A 47-year-old man with over 10 years’ duration of ulcerative colitis treated by 5-aminosalicylic acid and intermittent topical steroids complained of acute epigastric pain. Esophagogastroduodenoscopy revealed diffuse mucosal edema with patchy redness, multiple erosions and nodularity of the stomach. Bioptic examination revealed marked eosinophilic infiltration, confirming the diagnosis of eosinophilic gastroenteritis. Systemic steroid therapy was initiated, whereas his ulcerative colitis and eosinophilia recurred when tapering the steroid. Addition of azathioprine was ineffective, and we subsequently started vedolizumab for eosinophilic gastroenteritis and ulcerative colitis. The medication effectively improved his abdominal symptoms and esophagogastroduodenoscopy and ileocolonoscopy 1 year later revealed endoscopic improvement of both diseases with histologically decreased level of eosinophilic infiltration. Considering that eosinophils also express α4β7 integrins, vedolizumab can be a possible therapeutic candidate for eosinophilic gastroenteritis as well as ulcerative colitis.
  • 2,744 View
  • 161 Download
Close layer
Reviews
IBD
What to do when traditional rescue therapies fail in acute severe ulcerative colitis
Christopher F. D. Li Wai Suen, Matthew C. Choy, Peter De Cruz
Intest Res 2024;22(4):397-413.   Published online May 16, 2024
DOI: https://doi.org/10.5217/ir.2024.00003
AbstractAbstract PDFPubReaderePub
Acute severe ulcerative colitis (ASUC) is a medical emergency that affects approximately 25% of patients with ulcerative colitis at some point in time in their lives. Outcomes of ASUC are highly variable. Approximately 30% of patients do not respond to corticosteroids and up to 50% of patients do not respond to rescue therapy (infliximab or cyclosporin) and require emergency colectomy. Data are emerging on infliximab dosing strategies, use of cyclosporin as a bridge to slower acting biologic agents and Janus kinase inhibition as primary and sequential therapy. In this review, we outline contemporary approaches to clinical management of ASUC in the setting of failure to respond to traditional rescue therapies.

Citations

Citations to this article as recorded by  
  • Intensified infliximab induction therapy for steroid-refractory acute severe ulcerative colitis – Authors’ reply
    Christopher F D Li Wai Suen, Matthew C Choy, Danny Con, Peter De Cruz
    The Lancet Gastroenterology & Hepatology.2025; 10(1): 19.     CrossRef
  • Janus kinase inhibitors in the management of acute severe ulcerative colitis: a comprehensive review
    Javier P Gisbert, María Chaparro
    Journal of Crohn's and Colitis.2025;[Epub]     CrossRef
  • Sequential rescue therapy with JAK inhibitors in corticosteroid and infliximab-refractory acute severe ulcerative colitis: a case series
    Amirah Etchegaray, George Tambakis, Rina Kumar, Anthony Croft, Graham Radford-Smith, Gareth J. Walker
    Therapeutic Advances in Gastroenterology.2025;[Epub]     CrossRef
  • Population Pharmacokinetic Model for the Use of Intravenous or Subcutaneous Infliximab in Patients with Inflammatory Bowel Disease: Real-World Data from a Prospective Cohort Study
    Joo Hye Song, Sung Noh Hong, Myeong Gyu Kim, Minjung Kim, Seong Kyung Kim, Eun Ran Kim, Dong Kyung Chang, Young-Ho Kim
    Gut and Liver.2025; 19(3): 376.     CrossRef
  • Recent Advances in the Management of Acute Severe Ulcerative Colitis
    Elaine Ong Ming San, Kassem Sharif, Konstantina Rosiou, Michael Rennie, Christian Philipp Selinger
    Journal of Clinical Medicine.2024; 13(23): 7446.     CrossRef
  • 4,814 View
  • 349 Download
  • 6 Web of Science
  • 5 Crossref
Close layer
IBD
Korean clinical practice guidelines on biologics and small molecules for moderate-to-severe ulcerative colitis
Soo-Young Na, Chang Hwan Choi, Eun Mi Song, Ki Bae Bang, Sang Hyoung Park, Eun Soo Kim, Jae Jun Park, Bora Keum, Chang Kyun Lee, Bo-In Lee, Seung-Bum Ryoo, Seong-Joon Koh, Miyoung Choi, Joo Sung Kim, on behalf of the IBD Research Group of the Korean Association for the Study of Intestinal Diseases
Intest Res 2023;21(1):61-87.   Published online May 31, 2022
DOI: https://doi.org/10.5217/ir.2022.00007
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Ulcerative colitis (UC), a relapsing-remitting chronic inflammatory bowel disease (IBD), has a variable natural course but potentially severe disease course. Since the development of anti-tumor necrosis factor (TNF) agents has changed the natural disease course of moderate-to-severe UC, therapeutic options for patients who failed conventional treatments are expanding rapidly. IBD clinical trials have demonstrated the potential efficacy and safety of novel biologics such as anti-integrin α4β7 and anti-interleukin-12/23 monoclonal antibodies and small molecules such as a Janus kinase inhibitor. Anti-TNF biosimilars also have been approved and are widely used in IBD patients. Wise drug choices should be made considering evidence-based efficacy and safety. However, the best position of these drugs remains several questions, with limited data from direct comparative trials. In addition, there are still concerns to be elucidated on the effect of therapeutic drug monitoring and combination therapy with immunomodulators. The appropriate treatment regimens in acute severe UC and the risk of perioperative use of biologics are unclear. As novel biologics and small molecules have been approved in Korea, we present the Korean guidelines for medical management of adult outpatients with moderate-to-severe UC and adult hospitalized patients with acute severe UC, focusing on biologics and small molecules.

Citations

Citations to this article as recorded by  
  • Deep Learning Model Using Stool Pictures for Predicting Endoscopic Mucosal Inflammation in Patients With Ulcerative Colitis
    Jung Won Lee, Dongwon Woo, Kyeong Ok Kim, Eun Soo Kim, Sung Kook Kim, Hyun Seok Lee, Ben Kang, Yoo Jin Lee, Jeongseok Kim, Byung Ik Jang, Eun Young Kim, Hyeong Ho Jo, Yun Jin Chung, Hanjun Ryu, Soo-Kyung Park, Dong-Il Park, Hosang Yu, Sungmoon Jeong
    American Journal of Gastroenterology.2025; 120(1): 213.     CrossRef
  • Optimizing 5-aminosalicylate for moderate ulcerative colitis: expert recommendations from the Asia-Pacific, Middle East, and Africa Inflammatory Bowel Disease Coalition
    Filiz Akyüz, Yoon Kyo An, Jakob Begun, Satimai Aniwan, Huu Hoang Bui, Webber Chan, Chang Hwan Choi, Nazeer Chopdat, Susan J Connor, Devendra Desai, Emma Flanagan, Taku Kobayashi, Allen Yu-Hung Lai, Rupert W Leong, Alex Hwong-Ruey Leow, Wai Keung Leung, Ju
    Intestinal Research.2025; 23(1): 37.     CrossRef
  • Characteristics and outcomes of portal vein thrombosis in patients with inflammatory bowel disease in Korea
    Ki Jin Kim, Su-Bin Song, Jung-Bin Park, June Hwa Bae, Ji Eun Baek, Ga Hee Kim, Min-Jun Kim, Seung Wook Hong, Sung Wook Hwang, Dong-Hoon Yang, Byong Duk Ye, Jeong-Sik Byeon, Seung-Jae Myung, Suk-Kyun Yang, Chang Sik Yu, Yong-Sik Yoon, Jong-Lyul Lee, Min Hy
    The Korean Journal of Internal Medicine.2025; 40(2): 243.     CrossRef
  • Comparison of 1‐Year Clinical Course in Patients With Newly Diagnosed Inflammatory Bowel Disease Between Vietnam and Korea: A Multinational, Multicenter Retrospective Cohort Study
    Luan Minh Dang, Eun Soo Kim, Kyeong Ok Kim, Yoo Jin Lee, Hoang Huu Bui, Chuong Dinh Nguyen, Chi Thi Nguyen, Nam Hoai Nguyen, Hien Thi‐Thu Nguyen, Nga Thi Dinh, Lien Thi‐Phuong Nguyen, Khien Van Vu, Minh Cuong Duong
    JGH Open.2025;[Epub]     CrossRef
  • Temporal trends in obesity and its prognostic impact in Korean patients with inflammatory bowel disease
    Min Kyu Kim, Seung Hwan Shin, Cheol-Hyung Lee, Soyoung Kim, Jong Whan Kim, Songhyun Lee, Seung Wook Hong, Sang Hyoung Park, Dong-Hoon Yang, Byong Duk Ye, Jeong-Sik Byeon, Seung-Jae Myung, Suk-Kyun Yang, Sung Wook Hwang
    Journal of Gastroenterology.2025; 60(5): 583.     CrossRef
  • Metabolic musculoskeletal disorders in patients with inflammatory bowel disease
    Young Joo Yang, Seong Ran Jeon
    The Korean Journal of Internal Medicine.2025; 40(2): 181.     CrossRef
  • Annual Therapeutic Drug Monitoring in Patients with Inflammatory Bowel Disease During Infliximab Maintenance Therapy: Balancing Efficacy with Risk of Pharmacokinetic Failure
    Yujin Lim, Boram Park, Kyeongman Jeon, Ok Soon Jeong, Eun Ran Kim, Young-Ho Kim, Dong Kyung Chang, Sung Noh Hong
    Digestive Diseases and Sciences.2025;[Epub]     CrossRef
  • Impact of early aggressive treatment on long-term biochemical marker patterns in inflammatory bowel disease
    Yu Kyung Jun, Yonghoon Choi, Cheol Min Shin, Young Soo Park, Nayoung Kim, Dong Ho Lee, Soyeon Ahn, Hyuk Yoon
    Journal of Gastroenterology.2025; 60(7): 854.     CrossRef
  • Population Pharmacokinetic Model for the Use of Intravenous or Subcutaneous Infliximab in Patients with Inflammatory Bowel Disease: Real-World Data from a Prospective Cohort Study
    Joo Hye Song, Sung Noh Hong, Myeong Gyu Kim, Minjung Kim, Seong Kyung Kim, Eun Ran Kim, Dong Kyung Chang, Young-Ho Kim
    Gut and Liver.2025; 19(3): 376.     CrossRef
  • Optimizing Infliximab Use in Real-World Inflammatory Bowel Disease: Insights from a Population Pharmacokinetic Model Integrating Intravenous and Subcutaneous Formulations
    Sung Hoon Jung, Sang-Bum Kang
    Gut and Liver.2025; 19(3): 299.     CrossRef
  • Does statin have a chemopreventive effect in patients with ulcerative colitis?
    Yoon Suk Jung
    Intestinal Research.2025; 23(2): 113.     CrossRef
  • Herpes zoster infection in patients with inflammatory bowel disease
    Dong Hyun Kim, Sang-Bum Kang
    The Korean Journal of Internal Medicine.2025; 40(3): 347.     CrossRef
  • Parishin from Gastrodia elata ameliorates DSS induced colitis and anxiety-like behavior in mice by regulating intestinal barrier function and microviota-gut-brain axis
    Xiaoxue Liu, Hejiang Zhou, Na Yang, Lu-Jun Yang, Zheng-Ying Zi, Ya-Lan Han, Jinsong He, Ling-Yan Su
    Phytomedicine.2025; 145: 157019.     CrossRef
  • Impact of age at diagnosis on long‐term prognosis in patients with intestinal Behçet's disease
    Ji Young Chang, Soo Jung Park, Jae Jun Park, Tae Il Kim, Jae Hee Cheon, Jihye Park
    Journal of Gastroenterology and Hepatology.2024; 39(3): 519.     CrossRef
  • Factors Associated with Reaching Mid-Parental Height in Patients Diagnosed with Inflammatory Bowel Disease in Childhood and Adolescent Period
    So Yoon Choi, Sujin Choi, Byung-Ho Choe, Jae Hong Park, Kwang-Hae Choi, Hae Jeong Lee, Ji Sook Park, Ji-Hyun Seo, Jae Young Kim, Hyo-Jeong Jang, Suk Jin Hong, Eun Young Kim, Yeoun Joo Lee, Ben Kang
    Gut and Liver.2024; 18(1): 106.     CrossRef
  • Continued JAK inhibitor treatment on the risk of recurrent herpes zoster reactivation in patients with immune-mediated inflammatory diseases: A nationwide population-based study in South Korea
    Young-Eun Kim, Ye-Jee Kim, Dae Hyun Jeong, Seonok Kim, Min Jee Kim, Hyeon Hwa Kim, Kyung-Wook Jo, Sang Hyoung Park, Seokchan Hong
    Seminars in Arthritis and Rheumatism.2024; 65: 152362.     CrossRef
  • Predictors of histologic remission in patients with biologic-naïve, moderate-to-severe ulcerative colitis treated with first-line biologic agents and small-molecule drugs: a single-center, retrospective cohort study
    Kijae Jo, Kwang Woo Kim, Hyun Jung Lee, Jong Pil Im, Joo Sung Kim, Seong-Joon Koh
    Intestinal Research.2024; 22(4): 453.     CrossRef
  • Risk Factors of Pneumocystis jirovecii Pneumonia in Patients with Inflammatory Bowel Disease: A Nationwide Population-Based Study
    Jiyoung Yoon, Seung Wook Hong, Kyung-Do Han, Seung-Woo Lee, Cheol Min Shin, Young Soo Park, Nayoung Kim, Dong Ho Lee, Joo Sung Kim, Hyuk Yoon
    Gut and Liver.2024; 18(3): 489.     CrossRef
  • Optimal Treatment Approaches to Intestinal Behçet's Disease Complicated by Myelodysplastic Syndrome: The KASID and KSBD Multicenter Study
    Jung-Bin Park, So Jung Han, Seung Bum Lee, Dong Hyun Kim, Jae Hee Cheon, Sung Wook Hwang, Byong Duk Ye, Suk-Kyun Yang, Soo Jung Park, Sang Hyoung Park
    Yonsei Medical Journal.2024; 65(5): 265.     CrossRef
  • Is the writing on the wall? The relationship between the number of disease-modifying anti-inflammatory bowel disease drugs used and the risk of surgical resection
    Marc M. Mankarious, Alicia C. Greene, Eric W. Schaefer, Kofi Clarke, Afif N. Kulaylat, Nimalan A. Jeganathan, Michael J. Deutsch, Audrey S. Kulaylat
    Journal of Gastrointestinal Surgery.2024; 28(6): 836.     CrossRef
  • Clinical Significance of Prognostic Nutrition Index in Patients with Crohn’s Disease after Primary Bowel Resection
    Hyeon Woo Bae, Yong Joon Lee, Min Young Park, Seung Yoon Yang, Yoon Dae Han, Min Soo Cho, Hyuk Hur, Kang Young Lee, Jae Hee Cheon, Joseph C. Carmichael, Byung Soh Min
    Yonsei Medical Journal.2024; 65(7): 380.     CrossRef
  • Current Management of Acute Severe Ulcerative Colitis: New Insights on the Surgical Approaches
    Sara Lauricella, Francesco Brucchi, Federica Cavalcoli, Emanuele Rausa, Diletta Cassini, Michelangelo Miccini, Marco Vitellaro, Roberto Cirocchi, Gianluca Costa
    Journal of Personalized Medicine.2024; 14(6): 580.     CrossRef
  • Effectiveness of Switching to Subcutaneous Infliximab in Ulcerative Colitis Patients Experiencing Intravenous Infliximab Failure
    June Hwa Bae, Jung-Bin Park, Ji Eun Baek, Seung Wook Hong, Sang Hyoung Park, Dong-Hoon Yang, Byong Duk Ye, Jeong-Sik Byeon, Seung-Jae Myung, Suk-Kyun Yang, Sung Wook Hwang
    Gut and Liver.2024; 18(4): 667.     CrossRef
  • Biosimilars in the Era of Artificial Intelligence—International Regulations and the Use in Oncological Treatments
    Tomas Gabriel Bas, Vannessa Duarte
    Pharmaceuticals.2024; 17(7): 925.     CrossRef
  • Comparative risk of serious infections and tuberculosis in Korean patients with inflammatory bowel disease treated with non-anti-TNF biologics or anti-TNF-α agents: a nationwide population-based cohort study
    Min Jee Kim, Ye-Jee Kim, Daehyun Jeong, Seonok Kim, Seokchan Hong, Sang Hyoung Park, Kyung-Wook Jo
    Therapeutic Advances in Gastroenterology.2024;[Epub]     CrossRef
  • Development and Assessment of a Novel Ulcerative Colitis–Specific Quality of Life Questionnaire: A Prospective, Multi-Institutional Study
    Jihye Park, Hyun-Soo Zhang, Chung Mo Nam, Joo Sung Kim, Young-Ho Kim, Dong Il Park, Byong Duk Ye, Yoon Tae Jeen, Sehyun Kim, Jae Hee Cheon
    Yonsei Medical Journal.2024; 65(11): 636.     CrossRef
  • Prevalence and risk factors for gallstone and renal stone formation in patients with intestinal Behçet’s disease
    Jaewon Song, Soo Jung Park, Jae Jun Park, Tae Il Kim, Jihye Park, Jae Hee Cheon
    The Korean Journal of Internal Medicine.2024; 39(5): 770.     CrossRef
  • Safety and effectiveness of tofacitinib in Korean adult patients with ulcerative colitis: post-marketing surveillance study
    Hyuk Yoon, Byong Duk Ye, Sang-Bum Kang, Kang-Moon Lee, Chang Hwan Choi, Joo-young Jo, Juwon Woo, Jae Hee Cheon
    BMC Gastroenterology.2024;[Epub]     CrossRef
  • Effectiveness of Early Thiopurine Use in Korean Patients With Moderate-to-Severe Ulcerative Colitis
    Hye Kyung Hyun, Ji Won Kim, Jun Lee, Yoon Tae Jeen, Tae-Oh Kim, Joo Sung Kim, Jae Jun Park, SungNoh Hong, Dong Il Park, Hyun-Soo Kim, YooJin Lee, Eun Suk Jung, Youngdoe Kim, Su Young Jung, Jae Hee Cheon
    Journal of Clinical Gastroenterology.2024;[Epub]     CrossRef
  • Efficacy of Second-Line Biological Therapies in Moderate to Severe Ulcerative Colitis Patients with Prior Failure of Anti-Tumor Necrosis Factor Therapy: A Multi-Center Study
    Ji-Eun Na, Yong-Eun Park, Jong-Ha Park, Tae-Oh Kim, Jong-Yoon Lee, Jong-Hoon Lee, Su-Bum Park, Seung-Bum Lee, Seung-Min Hong
    Journal of Personalized Medicine.2024; 14(10): 1066.     CrossRef
  • Ganjiang Huangqin Huanglian Renshen Decoction protects against ulcerative colitis by modulating inflammation, oxidative stress, and gut microbiota
    Ce Zhou, Bo Peng, Mingxing Zhang, Yang Yang, Zelin Yi, Yinghua Wu
    Phytomedicine.2024; 135: 156172.     CrossRef
  • The role and prospect of tofacitinib in patients with ulcerative colitis
    Jun Lee
    Intestinal Research.2023; 21(1): 168.     CrossRef
  • Real-life effectiveness and safety of tofacitinib treatment in patients with ulcerative colitis: a KASID multicenter cohort study
    Seung Hwan Shin, Kyunghwan Oh, Sung Noh Hong, Jungbok Lee, Shin Ju Oh, Eun Soo Kim, Soo-Young Na, Sang-Bum Kang, Seong-Joon Koh, Ki Bae Bang, Sung-Ae Jung, Sung Hoon Jung, Kyeong Ok Kim, Sang Hyoung Park, Suk-Kyun Yang, Chang Hwan Choi, Byong Duk Ye
    Therapeutic Advances in Gastroenterology.2023;[Epub]     CrossRef
  • Safety of Biologic Therapy in Older Adults with Inflammatory Bowel Diseases
    Tae-Geun Gweon
    The Korean Journal of Gastroenterology.2023; 81(5): 230.     CrossRef
  • Risk of all-cause and cause-specific mortality associated with immune-mediated inflammatory diseases in Korea
    Oh Chan Kwon, See Young Lee, Jaeyoung Chun, Kyungdo Han, Yuna Kim, Ryul Kim, Min-Chan Park, Jie-Hyun Kim, Young Hoon Youn, Hyojin Park
    Frontiers in Medicine.2023;[Epub]     CrossRef
  • How have treatment patterns for patients with inflammatory bowel disease changed in Asian countries?
    Jihye Park
    Intestinal Research.2023; 21(3): 275.     CrossRef
  • Treatment of primary sclerosing cholangitis combined with inflammatory bowel disease
    You Sun Kim, Edward H. Hurley, Yoojeong Park, Sungjin Ko
    Intestinal Research.2023; 21(4): 420.     CrossRef
  • Characteristics and Treatment Outcomes of Transition among Patients with Inflammatory Bowel Disease
    Eun Jin Yoo, Sang-Hoon Cho, Soo Jung Park, Tae Il Kim, Won Ho Kim, Jae Hee Cheon
    Yonsei Medical Journal.2023; 64(9): 541.     CrossRef
  • 10 years of biologic use patterns in patients with inflammatory bowel disease: treatment persistence, switching and dose intensification – a nationwide population-based study
    Hee Moon Koo, Yu Kyung Jun, Yonghoon Choi, Cheol Min Shin, Young Soo Park, Nayoung Kim, Dong Ho Lee, Young Kee Shin, Hyuk Yoon
    Therapeutic Advances in Gastroenterology.2023;[Epub]     CrossRef
  • Network meta-analysis on efficacy and safety of different biologics for ulcerative colitis
    Xinqiao Chu, Yaning Biao, Chengjiang Liu, Yixin Zhang, Chenxu Liu, Ji-zheng Ma, Yufeng Guo, Yaru Gu
    BMC Gastroenterology.2023;[Epub]     CrossRef
  • Advancements in the Management of Moderate-to-Severe Ulcerative Colitis: A Revised 2023 Korean Treatment Guidelines
    Soo-Young Na
    The Korean Journal of Medicine.2023; 98(5): 223.     CrossRef
  • IBD barriers across the continents – East Asia
    Joyce Wing Yan Mak, Agnes Hiu Yan Ho, Siew Chien Ng
    Therapeutic Advances in Gastroenterology.2023;[Epub]     CrossRef
  • Evaluation of Bacterial and Fungal Biomarkers for Differentiation and Prognosis of Patients with Inflammatory Bowel Disease
    Hyuk Yoon, Sunghyouk Park, Yu Kyung Jun, Yonghoon Choi, Cheol Min Shin, Young Soo Park, Nayoung Kim, Dong Ho Lee
    Microorganisms.2023; 11(12): 2882.     CrossRef
  • “Theranekron: A Novel Anti-inflammatory Candidate for Acetic Acid-Induced Colonic Inflammation in Rats”
    Mehtap Savran, Halil Ascı, Yalcin Erzurumlu, Ozlem Ozmen, Ilter Ilhan, M. Cem Sırın, Nasif Fatih Karakuyu, Adnan Karaibrahimoglu
    Molecular Biology Reports.2022; 49(9): 8753.     CrossRef
  • 12,389 View
  • 1,180 Download
  • 42 Web of Science
  • 44 Crossref
Close layer
Original Articles
Infection
Diagnostic performance of noninvasive tests for cytomegalovirus ileocolitis: a systematic review and meta-analysis
Thanaboon Chaemsupaphan, Onuma Sattayalertyanyong, Julajak Limsrivilai
Intest Res 2025;23(2):213-224.   Published online January 14, 2025
DOI: https://doi.org/10.5217/ir.2024.00136
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Background/Aims
Diagnosis of cytomegalovirus (CMV) ileocolitis traditionally requires colonoscopy with tissue biopsy. Due to potential complications in high-risk patients, there is growing interest in serum and stool tests for diagnosing this condition. We aimed to evaluate the diagnostic accuracy of these noninvasive tests compared to traditional gold standards.
Methods
Two independent reviewers performed a comprehensive search on MEDLINE and Embase from inception up to October 1, 2023. Prospective and retrospective studies evaluating the performance of serum CMV polymerase chain reaction (PCR), serum CMV antigen (Ag), and stool CMV PCR in diagnosing CMV ileocolitis were included. Tissue histopathology or tissue CMV PCR served as reference standards. Diagnostic performances of each serum and stool test were calculated based on a meta-analysis using random-effects model.
Results
A total of 30 studies, comprising 23 studies of serum CMV PCR, 9 of serum CMV Ag, and 7 of stool CMV PCR, were included. The pooled sensitivity, specificity, and area under summary receiver operating characteristic curves were 62% (95% confidence interval [CI], 51%–72%), 90% (95% CI, 79%–96%), and 0.81 for serum CMV PCR, 38% (95% CI, 26%–51%), 94% (95% CI, 70%–99%), and 0.56 for serum CMV Ag, and 53% (95% CI, 35%–70%), 91% (95% CI, 84%–95%), and 0.84 for stool CMV PCR.
Conclusions
Serum and stool tests cannot replace colonoscopy for diagnosing CMV ileocolitis due to their low sensitivities but may be useful when colonoscopy is not feasible. Positive results can aid diagnosis, given their high specificities. Serum and/or stool CMV PCR are preferred over CMV Ag.
  • 1,253 View
  • 135 Download
Close layer
IBD
Filgotinib induction-study baseline characteristics of patients with ulcerative colitis who achieve sustained corticosteroid-free remission: post hoc analysis of the phase 2b/3 SELECTION study
Taku Kobayashi, Axel Dignass, Xavier Roblin, Yoshie Takatori, Toshihiko Kaise, Alessandra Oortwijn, Corinne Jamoul, Toshifumi Hibi
Intest Res 2025;23(1):65-75.   Published online June 14, 2024
DOI: https://doi.org/10.5217/ir.2024.00007
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Background/Aims
Obtaining and maintaining corticosteroid-free remission are important goals of treatment for ulcerative colitis (UC). Characteristics associated with achieving corticosteroid-free remission were assessed in filgotinib-treated patients in SELECTION, a 58-week, phase 2b/3 trial in moderately to severely active UC.
Methods
This post hoc analysis used data from filgotinib-treated patients receiving corticosteroids at maintenance baseline in SELECTION. Univariate logistic regression was performed to assess induction baseline characteristics associated with 6 months of corticosteroid-free remission at week 58, defined as clinical remission without using corticosteroids for at least 6 months.
Results
At maintenance baseline, 92 and 81 patients were receiving corticosteroids in the filgotinib 200 mg and filgotinib 100 mg groups, respectively. Age, body mass index, history of pancolitis, disease duration, fecal calprotectin levels, C-reactive protein levels, Mayo Clinic Score, concomitant corticosteroids, immunomodulators, and aminosalicylates had no statistically significant effect on the likelihood of achieving corticosteroid-free remission. Baseline characteristics associated with increased odds of corticosteroid-free remission were Mayo Clinic Endoscopic Subscore of 2 (vs. 3) in the filgotinib 200 mg and filgotinib 100 mg groups, and female (vs. male) sex, current (vs. former or never) smoking, and being biologic‑naive (vs. experienced) in the filgotinib 200 mg group.
Conclusions
Steroid tapering can be achieved in patients with UC receiving filgotinib 200 mg independently of baseline characteristics such as clinical activity and duration of illness. However, the likelihood of achieving corticosteroid-free remission was higher among patients who were biologic-naive, current smokers, had low endoscopic inflammatory burden and who were female.

Citations

Citations to this article as recorded by  
  • In which patients with ulcerative colitis would filgotinib be effective?
    Jihye Park
    Intestinal Research.2025; 23(1): 1.     CrossRef
  • 4,440 View
  • 224 Download
  • 1 Web of Science
  • 1 Crossref
Close layer
IBD
Long-term efficacy and safety of tofacitinib in patients with ulcerative colitis: 3-year results from a real-world study
Hiromichi Shimizu, Yuko Aonuma, Shuji Hibiya, Ami Kawamoto, Kento Takenaka, Toshimitsu Fujii, Eiko Saito, Masakazu Nagahori, Kazuo Ohtsuka, Ryuichi Okamoto
Intest Res 2024;22(3):369-377.   Published online July 16, 2024
DOI: https://doi.org/10.5217/ir.2023.00194
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Background/Aims
The efficacy and safety of tofacitinib for the treatment of refractory ulcerative colitis (UC) has been demonstrated in clinical trials. Although, a series of reports with real-world evidence of its short-term efficacy and safety profiles have already been published, reports of long-term real-world data have been limited. We aimed to show our 3-year evidence on the clinical use of tofacitinib for the treatment of UC, focusing on its efficacy and safety profiles.
Methods
A retrospective observational study was conducted on patients who started tofacitinib for active refractory UC at our hospital. The primary outcome was the retention rate until 156 weeks after initiating tofacitinib. The secondary outcomes were short-term efficacy at 4, 8, and 12 weeks; long-term efficacy at 52, 104, and 156 weeks; prognostic factors related to the cumulative retention rate; loss of response; and safety profile, including adverse events.
Results
Forty-six patients who were able to be monitored for up to 156 weeks after tofacitinib initiation, were enrolled in this study. Continuation of tofacitinib was possible until 156 weeks in 54.3%, with > 50% response rates and > 40% remission rates. Among patients in whom response or remission was achieved and tofacitinib was deescalated after 8 weeks of induction treatment, 54.3% experienced relapse but were successfully rescued by and retained on reinduction treatment, except for 1 patient. No serious AEs were observed in the study.
Conclusions
Tofacitinib is effective and safe as long-term treatment in a refractory cohort of UC patients in real-world clinical practice.

Citations

Citations to this article as recorded by  
  • In which patients with ulcerative colitis would filgotinib be effective?
    Jihye Park
    Intestinal Research.2025; 23(1): 1.     CrossRef
  • Tofacitinib for ulcerative colitis in Brazil: a multicenter observational study on effectiveness and safety
    Rogério Serafim Parra, Renata de Sá Brito Fróes, Daniela Oliveira Magro, Sandro da Costa Ferreira, Munique Kurtz de Mello, Matheus Freitas Cardoso de Azevedo, Aderson Omar Mourão Cintra Damião, Alexandre de Sousa Carlos, Luísa Leite Barros, Maria Luiza Qu
    BMC Gastroenterology.2025;[Epub]     CrossRef
  • State-of-the-Art Evidence for Clinical Outcomes and Therapeutic Implications of Janus Kinase Inhibitors in Moderate-to-Severe Ulcerative Colitis: A Narrative Review
    Yunseok Choi, Suhyun Lee, Hyeon Ji Kim, Taemin Park, Won Gun Kwack, Seungwon Yang, Eun Kyoung Chung
    Pharmaceuticals.2025; 18(5): 740.     CrossRef
  • Endo-histologic outcomes in patients with ulcerative colitis responding to tofacitinib
    Arshdeep Singh, Arshia Bhardwaj, Devanshi Jain, Riya Sharma, Dharmatma Singh, Ramit Mahajan, Kirandeep Kaur, Aminder Singh, Vikram Narang, Harpreet Kaur, Manavjot Singh, Pritish Gupta, Tanisha Sehgal, Vandana Midha, Ajit Sood
    Indian Journal of Gastroenterology.2025;[Epub]     CrossRef
  • Exploring the Factors Associated With the Discontinuation of Tofacitinib in Patients With Rheumatoid Arthritis: A Retrospective Cohort Study
    Li‐Huei Chiang, Chia‐Ling Yu, Tzu‐Cheng Tsai, Yao‐Fan Fang
    International Journal of Rheumatic Diseases.2025;[Epub]     CrossRef
  • 3,900 View
  • 198 Download
  • 6 Web of Science
  • 5 Crossref
Close layer
IBD
Efficacy and safety of mirikizumab as induction and maintenance therapy for Japanese patients with moderately to severely active ulcerative colitis: a subgroup analysis of the global phase 3 LUCENT-1 and LUCENT-2 studies
Taku Kobayashi, Katsuyoshi Matsuoka, Mamoru Watanabe, Tadakazu Hisamatsu, Fumihito Hirai, Joe Milata, Xingyuan Li, Nathan Morris, Vipin Arora, Tomoko Ishizuka, Koji Matsuo, Yoichi Satoi, Catherine Milch, Toshifumi Hibi
Intest Res 2024;22(2):172-185.   Published online April 25, 2024
DOI: https://doi.org/10.5217/ir.2023.00043
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Background/Aims
Mirikizumab is a p19-directed anti-interleukin-23 antibody with potential efficacy against ulcerative colitis (UC). We evaluated the efficacy and safety of mirikizumab in a Japanese subpopulation with moderately to severely active UC from the LUCENT-1 and LUCENT-2 studies.
Methods
LUCENT-1 and LUCENT-2 were phase 3, randomized, double-blind, placebo-controlled trials of mirikizumab therapy in adults with moderately to severely active UC. LUCENT-1 was a 12-week induction trial where patients were randomized 3:1 to receive intravenous mirikizumab 300 mg or placebo every 4 weeks (Q4W). Patients achieving a clinical response with mirikizumab following the induction study were re-randomized 2:1 to double-blind treatment with either mirikizumab 200 mg or placebo subcutaneously Q4W during the 40-week maintenance study. The primary outcomes were clinical remission at week 12 of LUCENT-1 and week 40 of LUCENT-2.
Results
A total of 137 patients enrolled in Japan were randomized to mirikizumab (n = 102) or placebo (n = 35). Compared with placebo, patients who received mirikizumab showed numerically higher clinical remission at week 12 of induction (32.4% [n = 33] vs. 2.9% [n = 1]) and at week 40 of maintenance (48.9% [n = 23] vs. 28.0% [n = 7]). A greater number of patients achieved key secondary endpoints in the mirikizumab group compared with placebo. The frequency of treatment-emergent adverse events was similar across mirikizumab and placebo groups. Efficacy and safety results observed in the Japanese subpopulation were generally consistent with those in the overall population.
Conclusions
Mirikizumab induction and maintenance treatments were effective in Japanese patients with moderately to severely active UC. No new safety concerns were identified.

Citations

Citations to this article as recorded by  
  • Efficacy and safety of IL-23 p19 inhibitors in the treatment for inflammatory bowel disease: a systematic review and meta-analysis
    Shuhan Wang, Hui Sun, Qian Wang, Han Xiao
    Frontiers in Pharmacology.2025;[Epub]     CrossRef
  • Real‐World Effectiveness and Safety of Mirikizumab Induction Therapy in Patients With Ulcerative Colitis: A Multicentre Retrospective Observational Study
    Yasuhiro Takagi, Toshiyuki Sato, Takanori Nishiguchi, Akira Nogami, Masataka Igeta, Soichi Yagi, Maiko Ikenouchi, Mikio Kawai, Koji Kamikozuru, Yoko Yokoyama, Toshihiko Tomita, Hirokazu Fukui, Masayuki Fukata, Taku Kobayashi, Shinichiro Shinzaki
    Alimentary Pharmacology & Therapeutics.2025; 61(12): 1923.     CrossRef
  • Mirikizumab – a new option in treatment of inflammatory bowel diseases
    Jakub Olszewski, Katarzyna Kozon, Magdalena Sitnik, Katarzyna Herjan, Karolina Mikołap, Bartłomiej Gastoł, Maciej Bara, Piotr Armański, Marcin Sawczuk
    Prospects in Pharmaceutical Sciences.2024; 22(3): 178.     CrossRef
  • Key Interleukins in Inflammatory Bowel Disease—A Review of Recent Studies
    David Aebisher, Dorota Bartusik-Aebisher, Agnieszka Przygórzewska, Piotr Oleś, Paweł Woźnicki, Aleksandra Kawczyk-Krupka
    International Journal of Molecular Sciences.2024; 26(1): 121.     CrossRef
  • 6,550 View
  • 311 Download
  • 4 Web of Science
  • 4 Crossref
Close layer
Letter to the Editor
IBD
Response: Comments on “Adequacy of sigmoidoscopy as compared to colonoscopy for assessment of disease activity in patients of ulcerative colitis: a prospective study”
Sameet Tariq Patel, Sanjay Chandnani, Pravin M Rathi
Intest Res 2025;23(2):227-228.   Published online April 29, 2025
DOI: https://doi.org/10.5217/ir.2024.00209
PDFPubReaderePub
  • 338 View
  • 17 Download
Close layer
Review
Microbiota
Gut microbiome on immune checkpoint inhibitor therapy and consequent immune-related colitis: a review
Sung Wook Hwang, Min Kyu Kim, Mi-Na Kweon
Intest Res 2023;21(4):433-442.   Published online August 29, 2023
DOI: https://doi.org/10.5217/ir.2023.00019
AbstractAbstract PDFPubReaderePub
Immune checkpoint inhibitors have dramatically revolutionized the therapeutic landscape for patients with advanced malignancies. Recently, convincing evidence has shown meaningful influence of gut microbiome on human immune system. With the complex link between gut microbiome, host immunity and cancer, the variations in the gut microbiota may influence the efficacy of immune checkpoint inhibitors. Indeed, some bacterial species have been reported to be predictive for cancer outcome in patients treated with immune checkpoint inhibitors. Although immune checkpoint inhibitors are currently proven to be an effective anti-tumor treatment, they can induce a distinct form of toxicity, termed immune-related adverse events. Immune-related colitis is one of the common toxicities from immune checkpoint inhibitors, and it might preclude the cancer therapy in severe or refractory cases. The manipulation of gut microbiome by fecal microbiota transplantation or probiotics administration has been suggested as one of the methods to enhance anti-tumor effects and decrease the risk of immune-related colitis. Here we review the role of gut microbiome on immune checkpoint inhibitor therapy and consequent immune-related colitis to provide a new insight for better anti-cancer therapy.

Citations

Citations to this article as recorded by  
  • Incidence and risk factors of immune checkpoint inhibitor-induced colitis in Korean patients with cancer
    Tae Kyun Kim, Hyun Seok Lee, Eun Soo Kim
    The Korean Journal of Internal Medicine.2025; 40(1): 49.     CrossRef
  • Hidden Partner of Immunity: Microbiome as an Innovative Companion in Immunotherapy
    Pyoseung Kim, Sunggeun Joe, Heeyoung Kim, Hyejeong Jeong, Sunghwan Park, Jihwan Song, Wondong Kim, Yong Gu Lee
    International Journal of Molecular Sciences.2025; 26(2): 856.     CrossRef
  • Effect of Probiotics on Improving Intestinal Mucosal Permeability and Inflammation after Surgery
    Min-Jae Kim, Young Ju Lee, Zahid Hussain, Hyojin Park
    Gut and Liver.2025; 19(2): 207.     CrossRef
  • Advances in Genitourinary Tumor Genomics and Immunotherapy
    Jasmine Vohra, Gabriela Barbosa, Lívia Bitencourt Pascoal, Leonardo O. Reis
    Genes.2025; 16(6): 667.     CrossRef
  • Polygonatum polysaccharides as gut microbiota modulators: implications for autophagy-dependent PD-L1 clearance in cancer immunotherapy
    Yongjie Li, Feng Jiang, Ting Wang, Min Zeng
    Frontiers in Nutrition.2025;[Epub]     CrossRef
  • Date yogurt supplemented with Lactobacillus rhamnosus (ATCC 53103) encapsulated in wild sage (Salvia macrosiphon) mucilage and sodium alginate by extrusion: The survival and viability against the gastrointestinal condition, cold storage, heat, and salt wi
    Mahsa Abbasi Saadi, Seyed Saeed Sekhavatizadeh, Hassan Barzegar, Behrooz Alizadeh Behbahani, Mohammad Amin Mehrnia
    Food Science & Nutrition.2024; 12(10): 7630.     CrossRef
  • Toxicity in the era of immune checkpoint inhibitor therapy
    Synat Keam, Naimah Turner, Fernanda G. Kugeratski, Rene Rico, Jocelynn Colunga-Minutti, Rayansh Poojary, Sayan Alekseev, Anisha B. Patel, Yuanteng Jeff Li, Ajay Sheshadri, Monica E. Loghin, Karin Woodman, Ashley E. Aaroe, Sarah Hamidi, Priyanka Chandrasek
    Frontiers in Immunology.2024;[Epub]     CrossRef
  • Endoscopic findings of immune checkpoint inhibitor-related gastrointestinal adverse events
    Min Kyu Kim, Sung Wook Hwang
    Clinical Endoscopy.2024; 57(6): 725.     CrossRef
  • Causality between gut microbiota, immune cells, and breast cancer: Mendelian randomization analysis
    Rui Lv, Danyan Wang, Tengyue Wang, Rongqun Li, Aiwen Zhuang
    Medicine.2024; 103(49): e40815.     CrossRef
  • 6,457 View
  • 332 Download
  • 11 Web of Science
  • 9 Crossref
Close layer
Letter to the Editor
IBD
Comments on “Adequacy of sigmoidoscopy as compared to colonoscopy for assessment of disease activity in patients of ulcerative colitis: a prospective study”
Sidharth Harindranath
Intest Res 2025;23(2):225-226.   Published online September 6, 2024
DOI: https://doi.org/10.5217/ir.2024.00072
PDFPubReaderePub

Citations

Citations to this article as recorded by  
  • Response: Comments on “Adequacy of sigmoidoscopy as compared to colonoscopy for assessment of disease activity in patients of ulcerative colitis: a prospective study”
    Sameet Tariq Patel, Sanjay Chandnani, Pravin M Rathi
    Intestinal Research.2025; 23(2): 227.     CrossRef
  • 1,603 View
  • 107 Download
  • 1 Crossref
Close layer
Review
IBD
The evolving understanding of histology as an endpoint in ulcerative colitis
Shintaro Akiyama, Yusuke Miyatani, David T. Rubin
Intest Res 2024;22(4):389-396.   Published online March 13, 2024
DOI: https://doi.org/10.5217/ir.2023.00120
AbstractAbstract PDFPubReaderePub
A therapeutic goal for patients with ulcerative colitis (UC) is deep remission including clinical remission and mucosal healing. Mucosal healing was previously defined by endoscopic appearance, but recent studies demonstrate that histological improvements can minimize the risks of experiencing clinical relapse after achieving endoscopic remission, and there is growing interest in the value and feasibility of histological targets of treatment in inflammatory bowel disease, and specifically UC. In this review article, we identify remaining challenges and discuss an evolving role of histology in the management of UC.

Citations

Citations to this article as recorded by  
  • Claudin-2 simplifies histological assessment of activity/remission of ulcerative colitis in real-life daily practice
    Gabrio Bassotti, Rachele Del Sordo, Francesco Lanzarotto, Sara Mino, Chiara Ricci, Vincenzo Villanacci
    European Journal of Gastroenterology & Hepatology.2025; 37(4): 409.     CrossRef
  • Role of 5-aminosalicylic acid in ulcerative colitis management in 8 Asian territories: a physician survey
    Julajak Limsrivilai, Allen Yu-hung Lai, Silvia T. H. Li, Murdani Abdullah, Raja Affendi Raja Ali, Satimai Aniwan, Hoang Huu Bui, Jen-Wei Chou, Ida Normiha Hilmi, Wee Chian Lim, Jose Sollano, Michelle Mui Hian Teo, Shu-Chen Wei, Wai Keung Leung
    Intestinal Research.2025; 23(2): 117.     CrossRef
  • Beyond mucosal healing: fecal calprotectin and the path toward histologic remission in ulcerative colitis
    Yehyun Park
    Intestinal Research.2025; 23(2): 115.     CrossRef
  • Patients with ulcerative colitis who have normalized histology are clinically stable after de-escalation of therapy
    Shintaro Akiyama, Joëlle St-Pierre, Cindy Traboulsi, Alexa Silfen, Victoria Rai, Tina G. Rodriguez, Amarachi I. Erondu, Joshua M. Steinberg, Seth R. Shaffer, Britt Christensen, David T. Rubin
    npj Gut and Liver.2024;[Epub]     CrossRef
  • 5,734 View
  • 388 Download
  • 3 Web of Science
  • 4 Crossref
Close layer

Intest Res : Intestinal Research
Close layer
TOP